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ABSTRACT 
 
 
Pioglitazone is a thiazolidinedione (TZD) insulin sensitizer approved for use in human 
type 2 diabetes mellitus.  In addition to improving glycemic control, lipid profiles, and pancreatic 
β-cell function in diabetics, pioglitazone decreases hepatic triglyceride content in humans with 
non-alcoholic fatty liver disease.  Cats, like humans, are predisposed by obesity to a form of 
diabetes characterized by peripheral insulin resistance and insulin secretory defects.  They are 
also prone to a syndrome of severe hepatic triglyceride accumulation (hepatic lipidosis) during 
periods of decreased food intake.  Therapeutic options for both diabetes and hepatic lipidosis in 
cats are limited, and additional treatment choices would be beneficial.  The primary goal of this 
dissertation was to evaluate the effects of pioglitazone on insulin sensitivity in obese, insulin-
resistant cats, to assess its potential for use in cats with diabetes mellitus.  A secondary goal was 
to explore a technique for noninvasive measurement of liver fat in cats, to facilitate further study 
of pioglitazone or other agents in feline hepatic lipidosis.  First, pharmacokinetic parameters for 
pioglitazone were determined in lean and obese cats, and data were used to design an oral dosing 
regimen for further study.  Second, 1 and 3 mg/kg dosages of oral pioglitazone (Actos
TM
) were 
administered to 12 obese, insulin-resistant cats in a placebo-controlled 3-way crossover design.  
Effects on insulin sensitivity were measured using intravenous glucose tolerance testing; 
additionally, indirect calorimetry was used to detect any species-specific effects of pioglitazone 
on substrate oxidation or energy expenditure.  Third, 
1
H magnetic resonance spectroscopy (
1
H 
MRS) was performed to determine hepatic fat content in the 12 obese cats and in 6 lean cats 
using a modification of established human methods, and fat content in liver samples from a 
separate group of 4 lean and 5 obese cats was also determined by chemical triglyceride assay.  
Oral pioglitazone was rapidly absorbed in cats, with a median bioavailability of 55% and a 
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median half-life of 3 h.  After 6 weeks of daily dosing, 3 mg/kg pioglitazone significantly 
increased insulin sensitivity, reduced insulin area under the curve during IVGTT, and lowered 
serum triglyceride and cholesterol concentrations in the obese cats.  No changes in substrate 
oxidation or energy expenditure were observed.  Pioglitazone concentrations after chronic dosing 
suggested dose-dependent absorption characteristics for this drug in cats.  In the 12 obese and 6 
lean cats, median liver fat percentages determined by 
1
H MRS (6.8% and 1.3% for the obese and 
lean cats, respectively), were similar to chemical assay values from the 5 obese and 4 lean cats 
(median liver fat 6% and 1.7%, respectively).  Data obtained from these studies demonstrate a 
positive effect of 3 mg/kg pioglitazone on insulin sensitivity and lipid metabolism in obese cats, 
and suggest that further evaluation of the drug in cats with diabetes mellitus or other metabolic 
disorders is warranted.  As well, they provide a foundation for continued development of 
1
H 
MRS techniques to quantify the effects of therapeutic interventions on liver fat in cats. 
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CHAPTER I 
 
 
 
 
Introduction 
 
 
 
 
1.1 Introduction 
 
Obesity is a significant problem in the domestic feline population (Scarlett et al., 1994; 
German, 2006). In both humans and cats, obesity is a risk factor for diabetes mellitus; obese cats 
are 2-4 times more likely to have the disease than are cats of normal body condition (Panciera et 
al., 1990; Scarlett & Donoghue, 1998). The mechanisms by which obesity predisposes to 
diabetes are unclear, but obese cats exhibit altered insulin secretion patterns and reduced 
peripheral insulin sensitivity (Biourge et al.,1997; Hoenig et al., 2000; Hoenig et al., 2007), and 
have subnormal expression of the insulin-sensitive glucose transporter GLUT4 (Brennan et al., 
2004). In one study, insulin sensitivity in obese cats was estimated to decrease by 30% with each 
kilogram of excess body weight (Hoenig et al., 2007). Impaired peripheral insulin sensitivity is 
accompanied by compensatory hyperinsulinemia, which can eventually exhaust the secretory 
capacity of pancreatic β-cells and result in overt diabetes (Hoenig et al., 2000).   
 Feline obesity also predisposes to dyslipidemia (Jordan et al., 2008), and to abnormal fat 
deposition in the liver (hepatic lipidosis) following a period of rapid weight loss. Hepatic 
lipidosis can occur in non-obese as well as obese cats, and its causes are not well understood 
(Brown et al., 2007).  However, this condition has some pathophysiologic similarities to human 
non-alcoholic fatty liver disease (NAFLD), a chronic hepatopathy associated with obesity, 
insulin resistance, and dyslipidemia (Holt et al., 2006; Ahmed & Byrne, 2009).  Both feline 
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hepatic lipidosis and NAFLD are characterized by elevated concentrations of circulating non-
esterified fatty acids (NEFAs) (Pazak et al., 1998; Holt et al., 2006; Brown et al., 2007). In 
hepatic lipidosis, these peripheral lipolytic products accumulate as triglyceride in hepatocytes, 
and can create life-threatening liver function deficits (Hall et al., 1997; Armstrong & Blanchard, 
2009).   
Current treatment options for feline diabetes with significant evidence of efficacy and 
safety include only insulin and the sulfonylureas.  Insulin must be given by injection and carries 
the risk of hypoglycemia, both of which can be concerns for owners of diabetic cats (Niessen et 
al., 2010). Sulfonylureas increase insulin secretion by inhibiting an ATP-dependent potassium 
channel on β-cell membranes. Glipizide, a member of this drug class, has been used in diabetic 
cats, but long-term treatment with glipizide results in amyloid deposition in pancreatic islets 
(Hoenig et al., 2000). No pharmacological treatments are available for hepatic lipidosis; only 
aggressive nutritional support via a feeding tube has been shown to improve survival (Armstrong 
& Blanchard, 2009).   
Thiazolidinediones (TZDs) are a class of oral antidiabetic drugs approved for human use.  
They are labeled for treatment of type 2 diabetes mellitus, and have recently shown therapeutic 
efficacy in patients with NAFLD (Belfort et al., 2006; Ahmed & Byrne, 2009).  TZDs are 
agonists of peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear transcription 
factor that is a key regulator of adipogenesis (Lehrke & Lazar, 2005).  The natural ligands for 
PPARγ are unknown, but the receptor possesses a low affinity for various endogenous fatty acids 
and eicosanoids (Walczak & Tontonoz, 2002).  PPARγ is expressed abundantly in adipose tissue, 
and at low levels in other tissues, including pancreatic β-cells (Walczak & Tontonoz, 2002; 
Lehrke & Lazar, 2005).   
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In diabetic humans and rodents, the effects of TZD administration are an increase in 
whole-body insulin sensitivity, reduction of triglyceride content in non-adipose tissues such as 
liver and skeletal muscle, and lowering of serum triglyceride and/or NEFA concentrations 
(Lehrke & Lazar, 2005; Rasouli et al., 2005; Ravikumar et al., 2008; Bajaj et al., 2010).  
Although the molecular mechanisms for these changes have yet to be completely elucidated, 
activation of PPARγ is known to induce expression of numerous genes involved in glucose and 
lipid metabolism, including fatty acid binding and transport proteins, lipoprotein lipase (LPL), 
phosphenolpyruvate carboxykinase (PEPCK), and GLUT4 (Sandouk et al., 1993; Walczak & 
Tontonoz, 2002). Mobilization of ectopic lipid may be linked to the adipogenic activities of 
PPARγ: agonist treatment increases the number of small, insulin-sensitive adipocytes in 
subcutaneous tissue, potentially shifting the balance for lipid uptake and storage away from liver 
and muscle (de Souza et al., 2001; Yki-Järvinen, 2004). Additionally, unlike sulfonylureas, 
TZDs appear to improve pancreatic β-cell function (Campbell et al., 2004; Gastaldelli et al., 
2007; Wajchenberg, 2007).  In human diabetics, this contributes to stable long-term glycemic 
control (Campbell et al., 2004; Wajchenberg, 2007).    
Because TZDs are effective for treatment of human type 2 diabetes, they may be a 
promising therapeutic option for diabetes in cats.  As well, because of their effects on lipid 
metabolism, they may be useful for treatment of feline hepatic lipidosis.  Darglitazone, an 
experimental TZD, improved glucose and NEFA disposal during glucose tolerance tests in obese 
cats, while simultaneously reducing insulin concentrations (Hoenig & Ferguson, 2003).  
However, darglitazone did not complete clinical development, and of the approved TZDs 
(troglitazone, rosiglitazone, and pioglitazone), only pioglitazone has remained available for 
general prescription.   
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The primary goal of this dissertation was to describe the pharmacokinetics and effect of 
pioglitazone in obese, insulin-resistant cats, to assess its potential for use in cats with diabetes 
mellitus.  A secondary goal was to explore a technique for noninvasive measurement of liver fat 
in cats, to facilitate further study of pioglitazone or other agents in feline hepatic lipidosis.  
Hypotheses were 1) that pioglitazone, appropriately dosed, would improve insulin sensitivity in 
obese cats, and 2) that 
1
H NMR spectroscopy could be successfully used to measure feline liver 
fat. Chapter 2 provides further explanation of the background and significance of this work.  
Chapters 3-5 address specific project aims, as described below.  The last chapter of this 
dissertation (Chapter 6) summarizes project conclusions and outlines possible directions for 
future research.     
 
Specific Aim #1: Determine the pharmacokinetic properties of pioglitazone in cats.  
Single oral and intravenous doses of pioglitazone were administered in a crossover fashion to six 
healthy lean and six obese cats.  Plasma drug concentrations were measured by high-
performance liquid chromatography (HPLC), pharmacokinetic parameters were calculated using 
commercial software, and the data were used to select appropriate dosages for further study.  
This work is detailed in Chapter 3.  
 
Specific Aim #2: Evaluate the effects of pioglitazone on insulin sensitivity, glucose 
clearance, and non-esterified fatty acid (NEFA) disposal in obese cats.   
To test the hypothesis that pioglitazone would improve indices of insulin sensitivity in cats, 1 
and 3 mg/kg dosages of pioglitazone were administered orally for 7 weeks to 12 obese cats, in a 
placebo-controlled 3-way crossover design.  Changes in insulin sensitivity were assessed via 
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intravenous glucose tolerance testing, with measurement of glucose, insulin, NEFAs, and the 
adipokines adiponectin and leptin.  Indirect calorimetry was also performed in order to detect 
any species-specific effects of pioglitazone on energy expenditure and substrate oxidation in 
cats.  This work is detailed in Chapter 4.  
 
Specific Aim #3: Investigate the use of 
1
H MRS as a technique for measurement of hepatic 
triglyceride in cats.   
1
H magnetic resonance spectroscopy (
1
H MRS) was performed in 6 lean and 12 obese cats using 
a modification of established human methods.  To determine biological plausibility of the 
obtained values, chemical triglyceride assay of liver samples was performed in a separate group 
of 4 lean and 5 obese cats.  This work is detailed in Chapter 5.  
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Chapter II 
 
 
 
 
Background and Significance 
 
 
 
 
2.1 Background and significance 
 
Feline obesity and insulin resistance 
At least 35% of domestic cats in the United States are overweight or obese (Scarlett et al., 
1994; Lund et al., 2005), and a similar prevalence has been reported in Europe (Russell et al., 
2000; Colliard et al., 2009).  The relatively high occurrence of obesity in pet cats has been linked 
to sedentary, indoor lifestyles and consumption of calorically dense diets, factors similar to those 
implicated in the human “obesity epidemic” (Scarlett et al., 1994; Lund et al., 2005).  Adipose 
tissue in mammals is now recognized as an endocrine organ rather than simply an inert storage 
depot, and accumulation of excess body fat has biochemical as well as mechanical consequences 
(Scherer, 2006).  Specifically, obesity is associated with insulin resistance, or a subnormal 
response to insulin in target tissues, in both humans and cats (Buse et al., 2003; Hoenig, 2012).  
a) Normal insulin secretion and action 
In a healthy animal, insulin is secreted from pancreatic ß-cells in a pulsatile fashion that 
reflects oscillations in plasma glucose concentration (Lefebvre et al., 1987; Buse et al., 2003). 
Glucose-stimulated insulin secretion is initiated when glucose diffuses into the ß-cell through 
glucose transporter 2 (GLUT2); phosphorylation by pancreatic glucokinase traps the glucose 
intracellularly and allows it to enter the glycolytic pathway.  ATP generation in glycolysis and/or 
oxidative phosphorylation causes blockade of ATP-dependent K
+
 channels on the β-cell 
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membrane, which promotes membrane depolarization and opening of voltage-gated calcium 
channels.  The resulting calcium influx is the trigger for exocytosis of insulin-containing 
vesicles. When a sufficiently high dose of glucose is administered intravenously, two phases of 
insulin secretion are visible: a rapid first phase caused by the discharge of insulin from a specific 
pool of readily releasable granules, and a prolonged second phase that corresponds to the 
magnitude of the glucose stimulus (Buse et al., 2003; Seino et al., 2011).  
Secreted insulin enters the circulation and binds to insulin receptors (IR), which are 
autophosphorylating tyrosine kinases located at the cell surface (Figure 2.1). After insulin 
binding, phosphorylation of multiple tyrosine residues on the intracellular subunits of the 
receptor allows recruitment and phosphorylation of scaffolding proteins, notably the insulin 
receptor substrates (IRS 1-4). Both phosphorylated IR and IRS interact with other proteins to 
initiate signaling cascades in metabolic and mitogenic pathways (Saltiel & Kahn, 2001).  
Downstream effectors of insulin signaling may be protein kinases and phosphatases, 
transcription factors, or proteins involved in vesicle trafficking (Saltiel & Kahn, 2001; Krüger, 
2008); the protein kinases phosphatidylinositol-3-kinase (PI(3)K) and Akt are key mediators of 
the effects of insulin in metabolic pathways, whereas PI(3)K and mitogen-activated protein 
kinases (MAP kinases) are important for its growth-promoting effects (Saltiel & Kahn, 2001).  
In many tissues, including muscle and fat, an acute effect of insulin stimulation is 
translocation of vesicles containing the glucose transporter GLUT-4 to the plasma membrane.  
This occurs through insulin receptor (IR)- and IRS-1-induced activation of small GTPases, and 
produces a dramatic increase in glucose uptake within seconds of insulin binding (Guyton & 
Hall, 2000; Leto & Saltiel, 2012).  The majority (at least 75%) of whole-body insulin-stimulated 
glucose uptake is mediated by skeletal muscle (Saltiel & Kahn, 2001; Leto & Saltiel, 2012).  IR 
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activation in muscle also causes rapid phosphorylation of the enzyme glycogen synthase kinase, 
reducing its inhibition of glycogen synthase and increasing storage of the entering glucose as 
glycogen.  In adipocytes, entering glucose forms alpha-glycerol phosphate, a precursor for 
triglyceride synthesis.  Insulin increases lipid uptake and storage in these cells by activating 
endothelial lipoprotein lipase (LPL), fatty acid transport proteins, and lipid synthetic enzymes. 
Additionally, activation of a cAMP-specific phosphodiesterase by insulin signaling in adipocytes 
inhibits the enzyme hormone-sensitive lipase, profoundly suppressing peripheral lipolysis and 
decreasing release of non-esterified free fatty acids (NEFAs) into circulation (Guyton & Hall, 
2000).  
In the liver, insulin signaling through IRS-2 increases the expression and activity of 
glucokinase and glycogen synthase, which cause glucose phosphorylation and glycogen storage, 
respectively. When hepatic glycogen stores are replete, excess glucose is metabolized by 
glycolysis, and insulin-mediated activation of the enzyme acetyl CoA carboxylase promotes the 
synthesis of triglycerides.  Ultimately, these triglycerides may be secreted as very low density 
lipoproteins (VLDL) (Guyton & Hall, 2000); however, VLDL production is acutely inhibited by 
insulin in the postprandial state (Gibbons et al., 2004).  Insulin signaling also inhibits hepatic 
glycogenolytic enzymes (glycogen phosphorylase and glucose-6-phosphatase), reduces the 
quantity and activity of enzymes required for gluconeogenesis (through antagonism of the 
transcription factor FOXO1 by Akt), and decreases the availability of gluconeogenic substrates 
by impeding protein catabolism in other tissues (Guyton & Hall, 2000; Kahl & Roden, 2012).  
These changes contribute to insulin-dependent suppression of hepatic glucose production. 
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b) Alterations in obesity 
In humans, obesity produces insulin resistance in all three major metabolic organs 
(skeletal muscle, adipose tissue, and the liver).  This has been demonstrated through the use of a 
multiple-dose euglycemic-hyperinsulinemic clamp (EHC) with isotopic tracers, which compared 
rates of peripheral glucose uptake, fatty acid (palmitate) appearance, and hepatic glucose 
production between lean and obese individuals at low and high physiologic insulin 
concentrations.  During the low-dose insulin infusions, glucose and palmitate rate of appearance 
(Ra, expressed per kilogram of fat-free mass) were not appropriately suppressed by insulin in 
obese subjects, and insulin-stimulated glucose uptake was decreased at all insulin infusion rates.  
Also, at all insulin infusion rates, systemic plasma insulin concentrations were 20-50% greater in 
obese than in lean subjects (Conte et al., 2012).  The latter finding reflects the fact that ß-cells 
respond to insulin resistance with a compensatory increase in insulin secretion (Kahn et al., 
1993; Buse et al., 2003).   
Although a multiple-dose EHC has not been reported in cats, reduced glucose clearance 
during intravenous glucose tolerance tests (IVGTT) has been documented in obese cats by 
multiple investigators (Biourge et al. 1997; Wilkins et al., 2004)).  As mentioned previously, one 
study using a single-dose EHC found that insulin sensitivity decreased by 30% for each 1-kg 
increase in body weight (Hoenig et al., 2007). Obese cats also exhibit basal hyperinsulinemia 
(Jordan et al., 2008; Hoenig et al., 2011) and exaggerated second-phase insulin secretion during 
IVGTT (Wilkins et al., 2004; Kley et al., 2008).  Additionally, they are dyslipidemic, with 
increased concentrations of triglyceride-rich VLDL and small dense LDL (Jordan et al., 2008).  
These lipoprotein changes occur when insulin fails to suppress VLDL secretion, and similar 
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abnormalities are seen in insulin-resistant humans and rodents (Ginsberg et al., 2005; Sørenson 
et al., 2011).     
The mechanisms by which obesity leads to insulin resistance are not well understood.   
However, abnormal fatty acid trafficking in human obesity appears to result in increased delivery 
of lipids to lean tissue, and in intracellular accumulation of lipid intermediates such as long chain 
fatty acyl CoAs (LC-FA CoAs), diacylglycerol (DAG), and ceramides (Samuel et al., 2009; 
McQuaid et al., 2011). These intermediates are thought to alter insulin signaling through 
phosphorylation of serine residues on the insulin receptor (IR) or its substrates (Muoio & 
Newgard, 2008). The link between lipid metabolites and serine phosphorylation may occur 
through isoforms of the protein kinase C (PKC) family (PKCФ in muscle, and PKCε in the 
liver), which are activated by DAG and other lipid derivatives (Peterson & Shulman, 2006; 
Muoio & Newgard, 2008; Kahl & Roden, 2012), or through activation of other serine kinases 
such as c-Jun N-terminal kinase (JNK) (Muoio & Newgard, 2008).  Potential triggers for the 
latter include metabolic overload in the endoplasmic reticulum (ER), and exposure to 
inflammatory cytokines such as TNF-α and IL-6 (Muoio & Newgard, 2008).  
Adipose tissue in obese humans and rodents is infiltrated by macrophages with a pro-
inflammatory phenotype (Wellen & Hotamsligil, 2005; Glass & Olefsky, 2012).  TNF-α and IL-
6 may be released either from these macrophages or from dysfunctional adipocytes, resulting in 
local and systemic elevations of inflammatory markers (Park et al., 2005; Glass & Olefsky, 
2012).  In contrast to the situation in humans, obesity-induced macrophage infiltration has not 
been reported in cats, and obese cats do not have elevated plasma concentrations of TNF-α or IL-
6 (Hoenig et al., 2013).  However, obese cats do have increased TNF-α mRNA in adipose tissue 
(Hoenig et al., 2006), suggesting inflammatory mediators may still participate in feline insulin 
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resistance by acting locally (Hoenig et al., 2013).  Obese cats are also likely to have abnormal 
fatty acid trafficking, as they have increased LPL expression in muscle, decreased LPL 
expression in adipose tissue, and elevated intramyocellular and extramyocellular lipid 
concentrations (Wilkins et al., 2004; Hoenig et al., 2006).   
Despite the presence of multi-organ insulin resistance in obesity, the basal rate of adipose 
tissue lipolysis is actually lower in obese than in lean humans (Mittendorfer et al., 2009), 
although total NEFA Ra and serum NEFA concentration may be greater because of increased fat 
mass (Karpe et al., 2009; Mittendorfer et al., 2009).  As well, a recent study of human VLDL 
kinetics found a lower rate of hepatic glucose production (per kilogram of fat-free mass) in obese 
than in lean men with normal glucose tolerance (Sørenson et al., 2011).   This is in harmony with 
other studies which have reported no increase in the basal rate of hepatic glucose production in 
otherwise healthy obese subjects (Gastaldelli et al., 2004).  Together, these findings illustrate that 
1) insulin resistance is manifest in a tissue-specific manner, consistent with different insulin 
dose-response relationships for different metabolic processes (Yki-Järvinen et al., 1987), and 2) 
under physiologic conditions, certain consequences of insulin resistance can be masked by 
compensatory hyperinsulinemia (Conte et al., 2012).  
Similar to the human situation, serum NEFA concentrations in obese cats are frequently, 
but not always, elevated (Wilkins et al., 2004; Jordan et al., 2008), and both fasting and 
postprandial hepatic glucose production are lower in obese cats than in lean cats when 
normalized for body weight (Kley et al., 2009; Hoenig et al., 2011).  As a result of their ability to 
maintain control of hepatic glucose production, obese cats have glucose concentrations similar to 
those of lean cats when monitored throughout the day (Hoenig et al., 2012).  Nonetheless, the 
underlying insulin resistance of obese cats is likely to contribute to their susceptibility to 
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metabolic disorders, including diabetes mellitus (Scarlett & Donoghue, 1998).  One potential 
explanation for the connection between obesity-induced insulin resistance and diabetes is that the 
ER stress, oxidative damage, and inflammatory changes resulting from fuel surfeit interfere with 
insulin signaling in ß-cells, as they do in other tissues (Prentki & Nolan, 2006).  Since insulin 
signaling is necessary for ß-cell growth and survival, such interference could ultimately promote 
ß-cell loss (Rhodes, 2005; Kasuga, 2006).  Another possible explanation involves the increased 
secretory demand associated with insulin resistance, which has been postulated to lead to 
depletion of pancreatic insulin stores and ß-cell exhaustion (Prentki & Nolan, 2006).  However, 
the latter mechanism has been demonstrated primarily in situtations of pre-existing ß-cell 
compromise (e.g. Matsuda, et al., 2002), and many obese cats and humans never develop 
diabetes, despite years of insulin resistance.  Therefore, apart from playing a direct role in ß-cell 
dysfunction, insulin resistance may simply increase the likelihood of metabolic decompensation 
when other genetic or environmental stresses on the ß-cell are present.  
 
Feline diabetes mellitus 
Diabetes mellitus (DM) affects 0.4-1% of domestic cats, and is more common in those 
that are male, neutered, aged, or inactive, in addition to those that are obese (Prahl et al., 2007; 
McCann et al., 2007).  In humans, DM is classified as type 1 or type 2 based on 
etiopathogenesis; type 1 is associated with absolute insulin deficiency and immune-mediated ß-
cell destruction, whereas type 2 is characterized by a combination of insulin resistance and 
potentially reversible ß-cell dysfunction.  The most frequently encountered form of DM in cats 
resembles human type 2 DM in several respects (Henson & O’Brien, 2006; Hoenig, 2012).  First, 
although diabetic cats have a 50% loss of ß-cell mass (O’Brien et al., 1986), it is not immune-
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mediated, as ß-cell antibodies have not been identified in untreated diabetic cats (Hoenig et al., 
2000b).  Second, the emergence of feline DM depends on the balance between insulin resistance 
and ß-cell function; induction of insulin resistance by corticosteroids, progestagens, or weight 
gain can precipitate clinical disease in susceptible individuals (Hoenig et al., 2000a; Sieber-
Ruckstuhl, 2008; Reusch, 2010).  Third, both human type 2 and feline DM are typified 
histologically by deposition of amyloid in pancreatic islets (O’Brien et al., 1986; Hoenig et al., 
2000a; O’Brien, 2002).     
Islet amyloid is found in 90% of human type 2 diabetics and in 65-90% of diabetic cats 
(Johnson et al., 1986; O’Brien, 2002).  It is derived from amylin, also called islet amyloid 
polypeptide (IAPP) (Westermark et al., 1987); this polypeptide is co-secreted with insulin, and, 
consequently, is hyper-secreted in insulin-resistant states (Henson et al., 2011).  In cats, humans, 
and certain non-human primates that develop type 2 DM (e.g. macaques, baboons), the 
midportion of amylin has an amino acid sequence that promotes the formation of secondary 
structure, including ß-pleated sheets and amyloid fibrils (Betsholtz et al., 1989; O’Brien, 2002; 
Guardado-Mendoza et al., 2009).  These amyloid aggregates are cytotoxic in vitro, as incubation 
of islets with amyloid fibrils, or expression of human amylin in cultured cells, results in 
apoptosis (O’Brien, 2002).   
In a study evaluating pancreatic lesions in 6 diabetic cats, 6 non-diabetic cats with 
impaired glucose tolerance (IGT), and 6 young non-diabetic cats with normal glucose tolerance 
(NGT), islet amyloid was absent in all cats with NGT, but was present in all diabetic cats and in 
2/6 nondiabetic cats with IGT (O’Brien et al., 1986).  In the diabetic cats and in the 2 IGT cats 
with amyloid deposits, ß-cell mass was decreased, suggesting a relationship between amyloid 
deposition and ß-cell apoptosis in vivo as well as in vitro (O’Brien et al., 1986).  Pancreatic 
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amyloid deposits are also present in approximately 45% of older non-diabetic cats, although they 
are not as extensive as in diabetic cats (Yano et al., 1981).  Therefore, amyloid deposition is not 
the sole determinant of ß-cell failure in feline DM; however, it may contribute by reducing ß-cell 
functional reserve (O’Brien, 2002; Henson & O’Brien, 2006).   
As discussed above, superimposition of insulin resistance on defective ß-cell function, or 
vice versa, is the likely trigger for clinical DM. One study has examined the progression to 
diabetes in partially pancreatectomized cats rendered insulin-resistant by administration of 
growth hormone and dexamethasone.  An early sign of developing DM in these cats was loss of 
first-phase insulin secretion; this was followed by a reduction in total insulin secretion and by 
development of abnormal glucose clearance.  Eventually, a further decline in insulin secretion 
allowed the onset of fasting hyperglycemia (Hoenig et al., 2000a).  The pattern of insulin 
secretory dysfunction during the onset of human type 2 DM is similar (Weyer et al., 1999), and 
in humans, the final increase in glucose concentration is due to a rise in endogenous glucose 
production (Weyer et al., 1999). 
Hyperglycemia in diabetic cats may perpetuate or worsen impaired ß-cell function.  The 
detrimental effects of hyperglycemia on ß-cell mass and function are referred to as glucotoxicity, 
and have been demonstrated in multiple species both in vitro and in vivo (Poitout & Robertson, 
2008).  In one study, chronic exposure of cultured ß-cells to high glucose concentrations reduced 
binding of the transcription factors MafA and PDX-1 to the insulin promoter, inhibiting insulin 
production and secretion. These effects were reversible when the cells were transferred to a low-
glucose medium (Poitout & Roberton, 2008).  A similar loss of insulin secretion occurs with 
hyperglycemia in numerous rodent models (Leahy et al., 1992), and in healthy cats, clamping of 
blood glucose at 30 mmol/L (540 mg/dL) for 10 days caused loss of glucose-stimulated insulin 
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secretion, depletion of pancreatic insulin stores, and ß-cell apoptosis (Zini et al., 2009).  Free 
fatty acids also impair insulin secretion, reduce insulin gene expression, and induce ß-cell death 
in vitro (lipotoxicity) (Poitout & Roberston, 2008).  In vivo, however, these effects are manifest 
only in the presence of high glucose concentrations (Poitout & Robertson, 2008).         
At the time of diagnosis, many diabetic cats have low to low-normal insulin 
concentrations, indicating substantial ß-cell functional deficits (Crenshaw & Peterson, 1996).  
However, recovery of ß-cell function and clinical remission can occur in some cats with 
appropriate treatment (Nelson et al., 1999; Zini et al., 2010).  Clinical remission is defined as 
maintenance of normoglycemia and lack of clinical signs of DM for at least one month after 
cessation of therapy (Zini et al., 2010). In one study of 10 cats with clinical remission, 6 cats had 
undetectable insulin concentrations prior to treatment, and all lacked an insulin secretory 
response to intravenous glucagon. After treatment with either insulin or glipizide (an insulin 
secretogogue), all 10 cats exhibited a normal response to glucagon stimulation (Nelson et al., 
1999).  Recovery of insulin secretion with reversion to a non-insulin-dependent state has also 
been described in humans treated for type 2 DM, either with insulin or with oral hypoglycemic 
agents (Weng et al., 2008).  This phenomenon is thought to result, at least in part, from 
alleviation of glucotoxicity (Weng et al., 2008). 
Diabetic remission in cats does not imply an absence of ß-cell pathology.  In the study by 
Nelson et al, 5/5 cats from which pancreatic biopsies were obtained had histologic abnormalities 
(consisting of decreased islet numbers, islet amyloidosis, vacuolar degeneration, and swollen ß-
cells) (Nelson et al., 1999).  Other studies have found that cats with diabetic remission are 
susceptible to relapse; in a retrospective examination of  275 diabetic cats admitted to a referral 
hospital, of which 50% achieved clinical remission, median remission duration was 114 days 
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(range, 30-3370 days) (Zini et al., 2010).  Therefore, cats that have been diabetic at any point in 
the past should always be considered at risk for future disease. 
Clinical signs associated with DM in cats are similar to those observed in other species, 
including polyuria, polydipsia, lethargy, and weight loss.  Appetite may be increased or 
decreased depending on the stage of disease (Crenshaw & Peterson, 1996).  On laboratory 
evaluation, hypercholesterolemia, hypertriglyceridemia, hyperbilirubinemia, and elevated liver 
enzymes are commonly present in addition to hyperglycemia and glycosuria (Crenshaw & 
Peterson, 1996); elevated liver enzymes and bilirubin are presumed to be due to hepatic lipid 
accumulation, which was identified at necropsy in 35% of diabetic cats in one study (Goossens et 
al., 1998). Other possible complications of feline DM are polyneuropathy, manifest as a 
plantigrade stance, and diabetic ketoacidosis (DKA).  DKA develops when absolute or relative 
insulin deficiency co-exists with an excess of counterregulatory hormones (Schade & Eaton, 
1979).  
Currently, the mainstay of treatment for feline DM is exogenous insulin, in conjunction 
with dietary management. Insulin treatment (typically with protamine zinc (PZI), glargine, or 
lente preparations) can achieve clinical control of DM in 60-85% of cats within 2-4 months 
(Michiels et al., 2008; Weaver et al., 2006; Nelson et al., 2009), and remission rates of  >50% 
have been reported when insulin is combined with a high-protein, low-carbohydrate diet 
(Bennett et al, 2006).  Potential drawbacks of insulin therapy include hypoglycemia, which 
occurs in 41-64% of insulin-treated cats and is symptomatic in up to 20% (Michiels et al., 2008; 
Nelson et al., 2009), and day-to-day variation in efficacy due to difficulties associated with 
product stability or injection technique (Reusch, 2010).  The need to give insulin by injection and 
20 
 
the possibility of hypoglycemia were both identified as concerns in a recent survey of diabetic 
cat owners (Niessen et al., 2010).   
Glipizide, as mentioned above, has also been used clinically in diabetic cats.  This drug is 
a member of the sulfonylurea class of insulin secretogogues, which act by binding to and 
inhibiting a K
+
 channel on ß-cell membranes. Unfortunately, glipizide is effective in only 30-
40% of diabetic cats (Feldman et al., 1997), and long-term treatment with glipizide leads to 
amyloid deposition in feline pancreatic islets (Hoenig et al., 2000a).  Hypoglycemia and 
hepatotoxicity are also potential adverse effects of glipizide treatment (Feldman et al., 1997). 
Given these limitations, other options for treatment of feline DM, especially for owners who are 
unwilling or unable to attempt insulin therapy, would be beneficial. A selection of other oral 
agents (acarbose, metformin) has been investigated in diabetic cats, but with little success 
(Mazzaferro et al., 2003; Nelson et al., 2004). 
 
Feline hepatic lipidosis 
Hepatic lipidosis (HL) is the most commonly diagnosed liver disease of cats in North 
America (Armstrong & Blanchard, 2009). It is characterized by marked hepatocellular 
triglyceride accumulation (averaging 34% of liver weight in affected cats) and usually develops 
after a period of partial or complete anorexia (Hall et al., 1997; Center et al., 1993; Armstrong & 
Blanchard, 2009).  Anorexia and HL can occur as a result of stress, diet changes, or accidental 
food restriction in otherwise healthy cats (designated primary HL), or can be related to the 
presence of concurrent disease (so-called secondary HL) (Armstrong & Blanchard, 2009). No 
breed or sex predisposition for feline HL is recognized, but, like feline DM, the disease is more 
common in obese cats than in cats of normal body condition (Center et al., 1993).   
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The pathogenesis of feline HL is thought to involve 1) a negative energy balance, 2) 
induction of hormonal alterations that promote excessive peripheral lipolysis, and 3) delivery of 
high levels of endogenous lipids to the liver (Armstrong & Blanchard, 2009).  In a study 
comparing hormone and lipid concentrations in cats with HL, anorexic cats with other liver 
disease (cholangiohepatitis), and healthy control cats, cats with HL had hypoinsulinemia, a 
decreased insulin:glucagon ratio, and a threefold elevation of serum NEFAs relative to control 
cats (Brown et al., 2000). Interestingly, mean serum NEFA concentration in HL cats was almost 
twice that of similarly anorexic cats with cholangiohepatitis, although this may have been a 
result of small sample size in the cholangiohepatitis group, or of difference in body condition 
between the groups (Brown et al., 2000).  NEFAs derived from peripheral lipolysis are the 
source of liver triglyceride in cats with HL; this is confirmed by the fact that liver lipid 
composition in HL cats, but not in control cats, corresponds closely with that of peripheral 
adipose depots (Hall et al., 1997).   
Peripheral lipolytic products delivered to the liver may be disposed of in one of two 
ways: transport into mitochondria for β-oxidation, or re-esterification and storage in cytosolic 
droplets (McGarry & Foster, 1980). A proportion of stored triglyceride is later secreted as VLDL 
(Gibbons et al., 2004).  β-oxidation would be expected to be particularly active in the fasting 
state, as production of malonyl CoA, the primary inhibitor of fatty acid transport into 
mitochondria, is diminished in the absence of insulin (McGarry et al., 1989). Indeed, cats with 
HL have elevated concentrations of the ketone β-hydroxybutyrate, an indirect product of β-
oxidation (Pazak et al., 1998).  Also, they have increased concentrations of VLDL, which are 
ascribed to an increase in VLDL secretion (Pazak et al., 1998).  Clearly, however, neither ß-
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oxidation nor VLDL secretion in HL cats occurs at a rate sufficient to prevent triglyceride 
accumulation.   
Some investigators have suggested that this is because of compartmentalization of 
triglyceride pools in the hepatocyte: triglyceride in vacuoles is destined for VLDL secretion, and 
whereas rates of both ß-oxidation and VLDL secretion are finite, the capacity for triglyceride 
storage is not (Pazak et al., 1998). Thus, excess NEFA delivery may promote excess triglyceride 
storage, which persists despite maximal ß-oxidation and VLDL secretion (Pazak et al., 1998).  
Others have focused on defects in mitochondrial or peroxisomal oxidation as the cause of failure 
to mobilize hepatic triglyceride (Ibrahim et al., 2003).  Carnitine is an essential component of 
carnitine palmitoyltransferase, the major mitochondrial fatty acid transporter; consequently, 
supplementation of this nutrient during fasting in cats has been investigated (Ibrahim et al., 
2003). L-carnitine supplementation increased fatty acid oxidation during weight loss in obese 
cats (Ibrahim et al., 2003), but did not attenuate liver lipid accumulation or prevent the 
development of experimentally induced HL (Blanchard et al., 2002; Ibraham et al., 2003).   
Among other supplements that have been examined for prevention of HL, only high 
dietary protein has been shown to have a beneficial effect (Biourge et al., 1994).  In obese cats 
undergoing 4 weeks of fasting, hepatic lipid accumulation still occurred in those fed a high-
protein diet, but to a lesser degree than in those fed high-carboydrate, high-fat, or control diets 
(Biourge et al., 1994).  A syndrome very similar to feline HL occurs in other small carnivores, 
including mink and European polecats (Bjornvad et al., 2004; Nieminen et al., 2009).  Therefore, 
the susceptibility of cats to HL may well be related to their unique metabolic needs and 
carnivorous status, although a deficiency of any particular nutrient has yet to be identified. 
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In cats with HL, excess hepatic triglyceride interferes with liver function and bile flow, 
producing clinical changes such as icterus, hyperbilirubinemia, elevated liver enzymes, and 
hypoalbuminemia (Center et al., 1993).  Vitamin-K responsive coagulopathy, presumed to be 
due to lack of absorption of fat-soluble vitamins, and electrolyte abnormalities may also occur 
(Armstrong & Blanchard, 2009).  The institution of aggressive nutritional support via 
nasoesophageal, esophagostomy, or gastrostomy tubes has improved the survival rate of cats 
with HL from close to 0% to 60-90% (Jacobs et al., 1989; Armstrong & Blanchard, 2009).  
However, these measures may not be feasible for some cat owners, and, as for feline DM, 
additional treatment options would be desirable.  
 
Thiazolidinediones  
Thiazolidinediones (TZDs, or “glitazones”) are orally administered insulin sensitizers 
marketed for use in human type 2 diabetes. The antihyperglycemic activity of this class of 
compounds was discovered empirically in the late 1970s by Takeda Chemical Industries, during 
an investigation of lipid-lowering compounds in diabetic rodent models (Sohda et al. 1982; 
Grossman & Lessem, 1997).  In diabetic rats and mice, TZDs reduced elevated plasma glucose, 
insulin, and triglyceride concentrations, improved insulin-stimulated peripheral glucose uptake, 
and reduced hepatic glucose production, without increasing insulin secretion or causing 
hypoglycemia (Ikeda et al., 1990; Sugiyama et al., 1990; Grossman & Lessem, 1997; Day, 
1999).  They also improved glucose tolerance and mitigated hyperlipidemia and 
hyperinsulinemia in nondiabetic obese rodents (Ikeda et al., 1990; Grossman & Lessem, 1997; 
Day, 1999).  In lean or streptozotocin-induced diabetic animals, however, TZDs did not alter 
glucose tolerance or plasma glucose concentration (Ikeda et al., 1990; Day et al, 1999). These 
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results suggested that the TZDs produced their effects by enhancing the action of insulin in 
insulin-resistant states (Ikeda et al., 1990; Hofmann & Colca, 1992; Grossman & Lessem, 1997).   
In the 1990s, three TZDs (troglitazone, rosiglitazone, and pioglitazone) were approved 
for treatment of human type 2 DM (Yki-Järvinen, 2004). Troglitazone was withdrawn from the 
US market in 2000 (three years after product launch) because of a low incidence of idiosyncratic 
liver toxicity, but rosiglitazone and pioglitazone became widely prescribed during the subsequent 
decade (Yki-Järvinen, 2004; Alexander et al., 2008).  In diabetic humans, TZDs improved 
glycemic control by increasing peripheral insulin sensitivity and reducing endogenous glucose 
production, similar to their effects in animal models (Aronoff et al., 2000; Yamasaki et al., 1997; 
Miyazaki et al., 2004; Yki-Järvinen, 2004). They also decreased fasting and/or postprandial 
NEFA concentrations and augmented insulin-mediated suppression of adipose tissue lipolysis 
(Mayerson et al., 2002; Goldberg et al., 2005; Tan et al., 2005; Gastaldelli et al, 2009).  The 
effects of TZDs on lipoproteins have been shown to vary depending on the specific agent: 
whereas pioglitazone decreases triglycerides, increases HDL cholesterol, lowers LDL particle 
number, and increases LDL particle size in human diabetics, rosiglitazone has opposite effects 
on triglycerides and LDL particle number, and increases HDL and LDL particle size and HDL 
particle number to a lesser degree (Goldberg et al., 2005). 
 In addition to their benefits in terms of glycemic control, TZDs improve indices of ß-cell 
function in human diabetes (Miyazaki et al., 2002; Ovalle & Bell, 2004; Gasteldelli et al., 2007; 
Kutoh & Fukushima, 2009).  Rosiglitazone has been demonstrated to restore first-phase insulin 
secretion during IVGTT, and both pioglitazone and rosiglitazone increase the disposition index 
(a measure of glucose-stimulated insulin secretion relative to insulin resistance) in diabetic 
patients (Gastaldelli et al., 2007). These data have been supplemented by an investigation in 
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rodent models, which showed that diabetes-induced changes in pancreatic islet structure, 
including depletion of secretory granules and infiltration of exocrine cells, were prevented by 
TZD treatment (Diani et al., 2004). Clinically, the consequences of ß-cell functional 
improvement and preservation by the TZDs are durable long-term glycemic control (Campbell et 
al., 2004; DeFronzo, 2010) and reduction of diabetes risk in susceptible populations (Xiang et 
al., 2006; DeFronzo et al., 2011).  In a large cohort of humans with impaired glucose tolerance 
(“prediabetics”), pioglitazone reduced the risk of conversion to diabetes by 72% (DeFronzo et 
al., 2011).       
TZDs were approved only for treatment of type 2 DM.  However, they have been 
investigated in several other insulin-resistant conditions, including lipodystrophies, polycystic 
ovary syndrome, and non-alcoholic fatty liver disease (NAFLD) (Yki-Järvinen, 2004). The latter 
is a term for a spectrum of conditions characterized by hepatic triglyceride accumulation, ranging 
from simple steatosis to severe steatohepatitis and fibrosis (Ahmed & Byrne, 2009).  Human 
NAFLD differs from feline hepatic lipidosis in that it typically develops in the context of 
overnutrition and hyperinsulinemia; however, it is similar in that it involves high circulating 
endogenous NEFAs, which are the source of stored triglyceride in hepatocytes (Byrne, 2012).  In 
both type 2 diabetic patients and in nondiabetic patients with NAFLD, TZDs reduce liver 
triglyceride by 30-50% (Belfort et al., 2006; Ravikumar et al, 2008; Yki-Järvinen, 2009).  
Pioglitazone also lowers intracellular triglyceride and long chain fatty acyl-CoA in muscle of 
diabetic subjects (Ravikumar et al., 2008; Bajaj et al., 2010).    
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Mechanism of action  
Although their mechanism of action was unknown at the time of discovery, it has since 
become clear that TZDs are agonists of the peroxisome proliferator activated receptor gamma 
(PPARγ) (Lehmann et al., 1995; Tontonoz & Spiegelman, 2008).  The PPARs (PPARα, PPAR 
ß/δ, and PPARγ) are transcription factors belonging to the nuclear hormone receptor 
superfamily; they have a wide tissue distribution and play key regulatory roles in metabolism, 
cellular differentiation, and cell growth (Menendez-Gutierrez, et al., 2012).  PPARγ, in 
particular, is crucial for adipocyte development, lipid transport and storage, and whole-body 
glucose homeostasis (Menendez-Gutierrez, et al., 2012).  Of the two protein isoforms of PPARγ 
that have been described, PPARγ1 is expressed at low levels in many tissues (most abundantly in 
colon, macrophages, and vascular endothelium), whereas PPARγ2 is highly expressed in 
adipocytes (Vidal-Puig et al., 1997; Zieleniak et al., 2008).   
Like other nuclear receptors that are heterodimeric with the retinoid X receptor (RXR) 
(e.g. thyroid hormone receptor), PPARγ is bound to co-repressors in the nucleus in its 
unliganded state.  Association with a PPARγ agonist stabilizes a receptor conformation that 
promotes dissociation of co-repressors, recruitment of co-activators, heterodimerization with 
RXRα, and binding of the complex to hormone response elements in DNA (Rosen & 
Spiegelman, 2001).  Genome-wide chromatin immunoprecipitation studies in adipocytes and 
macrophages have revealed thousands of functional binding sites for the PPARγ-RXRα 
heterodimer (Lefterova et al., 2010).  PPAR response elements (PPREs) tend to be in enhancer 
regions far from transcription start sites, analogous to the situation for glucocorticoid and other 
hormone receptors.  Many are adjacent to binding sites for CCAAT-enhancer binding protein α 
(C/EBPα), a transcription factor that participates in a self-reinforcing loop to perpetuate PPARγ 
27 
 
expression (Nielsen et al., 2008; Siersbæk et al., 2010).  The accessibility of PPREs to the 
PPARγ–RXRα complex is regulated by patterns of histone methylation that vary by cell type, 
allowing a tissue-specific gene expression profile (Lefterova et al., 2010; Siersbæk et al., 2010).   
In adipocytes and adipocyte precursors, PPREs are present in the majority of genes 
controlling glucose and lipid metabolism, including those coding for aP2/FABP4 (an adipocyte-
specific fatty acid binding protein), lipoprotein lipase (LPL), phosphoenolpyruvate 
carboxykinase (PEPCK), and acyl CoA synthetase (ACS) (Henke, 2004; Siersbæk et al., 2010; 
Nielsen et al. 2008).  Activation of PPARγ in preadipocytes or cultured 3T3 fibroblasts is 
sufficient to drive terminal adipocyte differentiation, characterized phenotypically by lipid 
accumulation and acquisition of insulin sensitivity (Wu et al., 1999; Tontonoz et al., 1994; Rosen 
& MacDougald, 2006).  In brown adipocytes, additional features of terminal differentiation are 
PPARγ-mediated increases in mitochondrial biogenesis and expression of the uncoupling protein 
1 (UCP1), a proton channel that allows dissipation of energy derived from oxidative 
phosphorylation as heat (Tai et al., 1996).  Ablation of PPARγ in mature white and brown 
adipocytes results in the loss of their typical phenotypes, disordered lipid storage, and necrosis 
within a few days (Wu et al., 1999; Imai et al., 2004), demonstrating that PPARγ is necessary for 
adipocyte survival and function as well as for adipogenesis.  PPARγ also controls expression of 
genes involved in lipid uptake and transport in other tissues, promotes cellular differentiation in 
macrophages, epithelium and placenta, and suppresses secretion of inflammatory molecules in 
both macrophages and adipocytes (Barak et al., 1999; Rosen & Spiegelman, 2001).   
A high-affinity natural ligand for PPARγ has not been identified.  However, the receptor 
possesses a low affinity for various endogenous fatty acids and eicosanoids (Walczak & 
Tontonoz, 2002), and has a relatively large hydrophobic ligand binding pocket that can 
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accommodate multiple ligands simultaneously (Liberato et al., 2012).  These characteristics have 
led to speculation that PPARγ functions as a “lipid sensor” that regulates metabolic processes in 
response to endogenous lipid cues (Henke, 2004; Lehrke & Lazar, 2005).  Structurally, the TZDs 
resemble fatty acids in some respects, having an acidophilic “head” group, a short spacer region, 
and a hydrophobic “tail.” The TZD “head” group forms hydrogen bonds with specific residues in 
the ligand-binding pocket of the receptor, fixing the position of the C-terminal activation 
function helix (AF2) and augmenting its ability to bind coactivators.  Variations in the cyclic 
“tail” among molecules in the TZD class confer different receptor affinities, transactivation 
potential, and clinical properties (Henke, 2004; Loiodice & Pochetti, 2011).  In addition to 
classical agonism of PPARγ, the presence of a TZD in the ligand-binding pocket may prevent 
post-translational receptor modifications that would suppress transcriptional activity (Floyd & 
Stephens, 2012); this has been demonstrated for rosiglitazone and the serine kinase Cdk5 (Choi 
et al., 2010).  
For the TZDs, adipose tissue is likely to be a major site of action through direct PPARγ 
activation.  PPARγ is abundant in mature adipocytes, and many more genes are differentially 
expressed in adipose tissue after TZD treatment than are affected in other tissues such as muscle 
and liver (Way et al., 2001; Rasouli et al., 2012). Proteins known to be upregulated in adipocytes 
by TZD treatment include glucose and fatty acid transporters (GLUT4, FATP1, CD36), fatty 
acid binding and sequestration proteins (aP2/FABP4, perilipin), glycerol channels (aquaporin 7), 
metabolic enzymes (LPL, PEPCK) and many others (Lefterova et al., 2010; Tontonoz & 
Spiegelman 2008; Henke, 2004; Nielsen et al., 2008). Also, selective PPARγ activation in 
mature adipocytes (by use of a gain-of-function fusion protein under the control of the aP2 
promoter) improves insulin sensitivity in mice to a degree similar to that seen with TZD 
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treatment (Sugii et al., 2009). Several hypotheses have been advanced to explain how activation 
of PPARγ in adipose tissue could affect whole-body insulin sensitivity.  Proposed mechanisms 
include 1) “fatty acid steal,” through which increased adipocyte differentiation and function 
redirects lipids from other tissues into adipose tissue for storage (Yki-Järvinen, 2004; Rasouli et 
al., 2005), and 2) altered secretion of adipose-derived cytokines and peptide hormones (Yki-
Järvinen, 2004; Ferré, 2004).   
“Fatty acid steal” and alleviation of lipotoxicity have been suggested to explain the 
effects of TZDs on both insulin sensitivity and ß-cell function (Yki-Järvinen, 2004; Gastaldelli et 
al., 2007; Rasouli et al., 2007).  After TZD treatment, declines in intracellular fat content 
correlate with increased insulin sensitivity in muscle and liver (Bajaj et al., 2010; Ravikumar et 
al., 2008), and declines in plasma free fatty acids correlate with increased insulin secretory 
response during oral glucose tolerance testing (Gastaldelli et al., 2007).  However, the ß-cell 
functional effects of the TZDs may also be mediated through direct PPARγ activation in the 
pancreas (Leahy, 2009).  The pro-differentiation transcription factor PDX-1, which increases at a 
pivotal time during ß-cell compensation in partially pancreatectomized rats (Moibi et al., 2007), 
is regulated by TZDs through a PPRE in its promoter (Gupta et al., 2008).         
With regard to the second hypothesis (adipose tissue cross-talk through secretory 
products), TZDs increase plasma concentrations of adiponectin, an adipose-derived cytokine, in 
humans and rodents (Maeda et al., 2001).  This takes place through changes in both adiponectin 
expression (Maeda et al., 2001; Iwaki et al., 2003) and secretion (Bodles et al., 2006).  In 
humans, the increase in adiponectin concentration occurs early during the course of treatment 
(Hammarstedt et al., 2005).   It has been documented in lean individuals as well as in obese, 
insulin-resistant, and diabetic subjects (Maeda et al., 2001; Yu et al., 2002), and its significance 
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in terms of insulin sensitization is not completely clear.  However, adiponectin is known to 
improve hepatic insulin sensitivity in multiple species (Turer & Scherer, 2012), and in diabetic 
humans treated with pioglitazone, plasma adiponectin concentrations increase in proportion to 
decreasing liver fat and hepatic insulin resistance (Bajaj et al., 2004). In addition to its insulin-
sensitizing effects, adiponectin has anti-apoptotic effects on ß-cells in vitro, which appear to be 
mediated by reduction of ceramide concentrations (Turer & Scherer, 2012).   
PPARγ-independent mechanisms of action for TZDs have also been proposed.  For 
example, several members of this class bind to proteins found in the mitochondrial membrane 
(Colca et al., 2003; Bolten et al., 2007; Chen et al., 2012).  In a recent investigation, a novel 
compound that bound mitochondria with similar affinity, but was a very weak PPARγ agonist, 
was shown to be as effective as other TZDs at lowering blood glucose in ob/ob mice (Chen et al., 
2012).  Also, in cell culture or isolated tissues, some TZDs induce Akt phosphorylation or 
activation of AMP-dependent kinase (a fuel-sensing regulatory enzyme) more rapidly than 
would be expected for a transcriptional effect (LeBrasseur et al., 2006; Bolten et al., 2007). 
Debate persists regarding the relative importance of PPARγ agonism and other mechanisms in 
the pharmacology of the TZDs.  However, their agonism of the receptor is likely to account for 
at least some of their clinical properties.   
 
Adverse effects 
Dose-dependent adverse effects of the TZDs in both humans and animals include weight 
gain, mild, reversible anemia, and fluid retention (US FDA, 1999, Part 5; Aleo et al., 2003; 
Berria et al., 2007; Barnett, 2009.)   Some of these effects are likely to be PPARγ-mediated; for 
example, fluid retention is thought to involve activation of PPARγ in the renal collecting duct, 
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with consequent changes in epithelial transport proteins (Pavlov et al., 2010).  For others, the 
involvement of PPARγ has not been clarified.  Hematocrit reduction (approximately 3%) occurs 
in the absence of a significant change in total body water in humans, and a mild bone marrow 
suppressive effect of the TZDs has been suggested (Berria et al., 2007).  Weight gain typically 
amounts to 3-4 kg in obese humans over several months (Barnett, 2009).  It occurs primarily as 
an increase in subcutaneous fat (Berria et al., 2007); although this has been ascribed to the 
adipogenic activities of PPARγ, it can be prevented with a portion-controlled diet (Martin et al., 
2010).     
 TZD-induced fluid retention in humans may be manifest as peripheral or macular edema, 
or as an increased risk of congestive heart failure (Barnett, 2009).  The latter was added as a 
boxed warning to the label for both pioglitazone and rosiglitazone during the postmarketing 
period (Starner et al., 2008).  Other adverse effects recognized after marketing included distal 
limb fractures in women (both rosiglitazone and pioglitazone) (Loke et al., 2009), and a possible 
increase in the long-term risk of bladder cancer (pioglitazone) (Lewis et al., 2011). Bladder 
cancer was identified only in male rats during preclinical investigation of pioglitazone (US FDA, 
1999, Part 6); as well, for other adverse effects, species susceptibility was variable (US FDA, 
1999, Part 6).   
 In 2011, an increased incidence of cardiovascular adverse events was documented in 
rosiglitazone-treated patients, leading to the removal of rosiglitazone from non-US markets and 
its placement on a restricted prescription list in the US (Blind et al., 2010; US FDA, 2011).  
Thus, at the time of writing, pioglitazone is the only TZD available for general prescription. 
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Summary and implications 
The potential benefits of TZDs in feline metabolic disorders formed the foundation for 
the work described in the remainder of this dissertation.  First, in light of the pathophysiological 
similarities between human type 2 and feline DM, TZDs may be useful for treatment of DM in 
cats.  Possible advantages of TZDs over current treatment options might include 1) dual effects 
on insulin sensitivity and ß-cell function, 2) oral administration, 3) lag time to dissipation of 
effects, and 4) less risk of hypoglycemia.  In the studies described here, pioglitazone was 
selected for investigation because of commercial availability, and obese cats were used as a 
model for drug effects due to their naturally occurring insulin resistance. As dose-concentration 
relationships for pioglitazone vary among species (US FDA, 1999, Part 6), a pharmacokinetic 
study was first conducted in order to select an appropriate dosage.  
Second, the ability of TZDs to mobilize ectopic lipid may be of benefit in feline hepatic 
lipidosis. In humans, 
1
H magnetic resonance spectroscopy (
1
H MRS) is commonly used to 
measure hepatic triglyceride in clinical research (Schwenzer et al., 2009).  
1
H MRS has been 
used in cats to measure triglyceride in muscle (Wilkins et al., 2004); in the work described in 
Chapter 5 of this dissertation, it was applied to measurement of feline liver fat.  Historically, 
evaluation of the impact of drugs, diet composition, or other variables on liver lipid in cats has 
depended on histological or chemical examination of sequential liver biopsies (Biourge et al., 
1994; Blanchard et al., 2002; Ibrahim et al., 2003). However, histological examination is not 
ideal for precise quantification, and biopsy is an invasive procedure that carries the risk of 
hemorrhage or iatrogenic damage to perihepatic structures (Armstrong & Blanchard, 2009). The 
main advangates of 1H MRS over previous approaches are its noninvasive nature and ability to 
accurately quantify tissue fat content (Schwenzer et al., 2009). 
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2.2 Figures and Legends 
 
Figure 2.1  Insulin signaling.  Reprinted by permission from MacMillan Publishers Ltd: Nature 
414:799-806, © 2001. 
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Chapter III 
 
 
 
 
Pharmacokinetics of Pioglitazone in Lean and Obese Cats
1
 
 
 
        
3.1 Abstract  
Pioglitazone is a thiazolidinedione insulin sensitizer that has shown efficacy in type 2 diabetes 
and non-alcoholic fatty liver disease in humans. It may be useful for treatment of similar 
conditions in cats.  The purpose of this study was to investigate the pharmacokinetics of 
pioglitazone in lean and obese cats, in order to provide a foundation for assessment of its effects 
on insulin sensitivity and lipid metabolism.  Pioglitazone was administered intravenously 
(median 0.2 mg/kg) or orally (3 mg/kg) to 6 healthy lean (3.96 ±0.56 kg) and 6 obese (6.43 
±0.48 kg ) cats, in a two by two Latin Square design with a 4-week washout period.  Blood 
samples were collected over 24 hours, and pioglitazone concentrations were measured via a 
validated HPLC assay.  Pharmacokinetic parameters were determined using two-compartmental 
analysis for IV data and noncompartmental analysis for oral data.  After oral administration, 
mean bioavailability was 55%, t1/2 was 3.5 h, Tmax was 3.6 h, Cmax was 2131 ng/mL, and AUC0-inf 
was 15556 ng/mL*h.  There were no statistically significant differences in pharmacokinetic 
parameters between lean and obese cats following either oral or intravenous administration.  
Systemic exposure to pioglitazone in cats after a 3 mg/kg oral dose approximates that observed 
in humans with therapeutic doses.       
 Key Words: Pioglitazone, diabetes, hepatic lipidosis, pharmacokinetics, thiazolidinediones 
                                                     
1 Previously published.  Clark, M.H., Hoenig, M., Ferguson, D.C., Dirikolu, L. (2012) Pharmacokinetics of 
pioglitazone in lean and obese cats.  Journal of Veterinary Pharmacology and Therapeutics, 35(5):428-436. 
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3.2 Introduction 
 The incidence of obesity in cats has risen dramatically in the last three decades.  In both 
humans and cats, obesity leads to altered insulin secretion and sensitivity, and is a risk factor for 
type 2 diabetes mellitus (Strauss et al., 1974; Hoenig, 2002; Hoenig, 2006; Hoenig et al., 2007).  
Feline obesity also predisposes to dyslipidemia (Jordan et al., 2008), and to abnormal fat 
deposition in the liver (hepatic lipidosis) following a period of rapid weight loss. Hepatic 
lipidosis can occur in non-obese as well as obese cats, and its causes are not well understood 
(Brown et al., 2007); however, this condition has some pathophysiologic similarities to human 
non-alcoholic fatty liver disease (NAFLD), a chronic hepatopathy associated with obesity, 
insulin resistance, type 2 diabetes, and dyslipidemia (Pazak et al., 1998; Brown et al., 2007; Holt 
et al., 2006; Ahmed & Byrne, 2009).    
 Thiazolidinediones (TZDs) are a relatively new class of antidiabetic drugs approved for 
human use.  They are labeled for adjunctive treatment of type 2 diabetes mellitus, and have 
recently shown therapeutic efficacy in patients with NAFLD (Ahmed & Byrne, 2009).   TZDs 
are agonists of peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear 
transcription factor that is a key regulator of adipogenesis (Lehrke & Lazar, 2005).  The effects 
of TZD administration are an increase in whole-body insulin sensitivity, and reduction of 
triglyceride content in non-adipose tissues such as liver and skeletal muscle (Lehrke & Lazar, 
2005; Rasouli et al., 2005; Ravikumar et al., 2008; Bajaj et al., 2010).   
      Because the TZDs are effective for treatment of diabetes and NAFLD in people, they 
may be a promising therapeutic option for similar conditions in cats.  In fact, treatment with 
darglitazone (an experimental TZD) for 6 weeks resulted in marked improvement in lipid and 
glucose metabolism in obese, insulin-resistant cats (Hoenig & Ferguson, 2000).   The purpose of 
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this project was to describe the pharmacokinetics of the TZD pioglitazone in healthy lean and 
obese cats, in order to provide a foundation for the further study of this medication in cats with 
insulin resistance and hepatic lipid accumulation.  A secondary purpose of the project was to 
investigate whether the pharmacokinetic parameters of pioglitazone are altered in obese cats, 
since potential clinical use of the drug would involve this subpopulation.   
 
3.3 Materials and Methods 
 Animals  
 Six healthy lean (3.96 ±0.56 kg; median age 4 years, range 3-8 years) and six obese (6.43 
±0.48 kg; median age 5 years, range 4-8 years) neutered male Domestic Shorthair cats were used 
for this study.  The cats were individually housed at the University of Illinois veterinary medical 
animal care facility.  All procedures involving this study were approved by the university's 
Institutional Animal Care and Use Committee, and were conducted in accordance with 
guidelines established by the Animal Welfare Act and the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals. Food intake was adjusted to maintain a stable body 
weight. 
 Drug administration and sampling 
 Twenty-four to thirty-six hours before each study period, cats were sedated with 
tiletamine/zolazepam (Telazol™, Fort Dodge, IA, USA; 2-4 mg/kg intramuscularly based upon 
tiletamine) to facilitate placement of jugular and cephalic catheters.  Throughout the study, 
catheter patency was maintained by flushing with sterile 0.38% sodium citrate.   
 In each study period, each cat was administered a single dose of pioglitazone either 
intravenously (1 mg/kg) or orally (3 mg/kg).  After a washout period of at least 4 weeks, each cat 
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received the opposite formulation, in a two by two Latin Square design.  Food was withheld for 
12 hours before and 24 hours after drug administration.      
 For IV administration, pioglitazone HCl (Allichem LLC, Savage, MD, USA) was 
dissolved in medical grade dimethylsulfoxide (DMSO; 1 mg/100 µL) and diluted with fresh 
feline plasma and sterile 0.9% saline (10:45:45 DMSO:plasma:saline, v/v/v) to make a solution 
that contained 1 mg/mL pioglitazone base.  Plasma had been collected the previous day from the 
same cat to which it was to be administered, and the plasma:saline mixture had been filtered 
through a 0.2 µM nylon syringe filter (Fisher Scientific, Pittsburgh, PA, USA) to remove 
particulates.  The final pioglitazone solution was also filtered before administration to ensure 
sterility, and post-filtration samples were reserved for measurement of actual pioglitazone 
concentration to determine the IV dose administered to each cat.  The solution was injected 
through a jugular or cephalic catheter over 5 minutes.    
 For oral administration, commercially available pioglitazone tablets (Actos
TM
, Takeda 
Pharmaceuticals America, Inc., Deerfield, IL, USA) were crushed with a mortar and pestle and 
placed in gelatin capsules.  Capsules were weighed before and after filling to determine the 
actual weight of ground tablet, and were administered with a small amount of canned cat food 
(Purina NF, Nestlé Purina, St. Louis, MO, USA).  Cats were observed to be sure they had 
consumed the entire capsule.  
   Blood samples were obtained from the jugular catheter at 0, 5, 10, 15, 30 and 45 minutes, 
then at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, and 24 hours after IV drug administration.  After oral 
administration, samples were collected at 0, 15, 30 and 45 minutes, then at 1, 2, 3, 4, 5, 6, 8, 10, 
12, 14, and 24 hours. Samples were placed in EDTA microcentrifuge tubes and kept on ice until 
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centrifugation (10 minutes at 5000 x g), and the plasma was collected and stored at -20
o
C until 
assayed.  Cats were monitored for clinical abnormalities throughout the sample collection period.  
 
Measurement of pioglitazone concentrations 
a. Sample preparation 
 Plasma pioglitazone concentrations were measured by high performance liquid 
chromatography (HPLC), using a modification of previously published methods for quantitation 
of TZDs in plasma (Zhong & Williams, 1996; Michels et al., 2000). All chemicals were HPLC 
grade.  Methyl-4-hydroxybenzoate (Sigma Chemical Co., St. Louis, MO, USA) was used as an 
internal standard (IS).  Standard solutions (1 mg/mL) were prepared by dissolving pioglitazone 
and IS separately in acetonitrile:water (50:50, v/v) and acetonitrile, respectively.  The standard 
solutions were diluted with acetonitrile:water (50:50, v/v) to produce working standards, and the 
working standards of pioglitazone were added to blank feline plasma to prepare a calibration 
curve ranging from 2.5 ng-500 ng pioglitazone.   
b.  Extraction method 
 For extraction, IS (25 L of 10 ng/ L), acetonitrile (100 L), and ethyl acetate:hexane 
(90:10; 2 mL) were added to 200 or 250 L of each standard or subject sample (250 L for IV 
samples, and 200 L for oral samples).  After vortexing, the samples were centrifuged at 2,095 x 
g for 15 min.  The organic layer was separated and evaporated to dryness under a stream of N2 at 
40º C, using silanized taper bottom tubes.  The residue was resuspended in 100 L of 
acetonitrile:water (50:50, v/v) , vortexed, and transferred to a  vial for HPLC analysis. 
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c.  Instrumentation 
Twenty-five L of each sample or standard was injected onto an Agilent HPLC 1100 
system with a Phenomenex Luna C18 (250 mm x 4.6 mm x 5 M) column.  Mobile phase 
consisted of 78% Solvent A (0.25% acetic acid in water) and 22% Solvent B (0.25% acetic acid 
in acetonitrile), changing to 60% Solvent A/40% Solvent B over 10 minutes. Flow rate was 1 
mL/min., and the diode array detector was set for single wavelength acquisition at 269 nm with a 
12 nm span.  Under these conditions, pioglitazone and IS eluted at approximately 8 min and 11 
min, respectively.   
Pioglitazone concentration was determined from pioglitazone:IS peak area after linear 
regression analysis of the calibration standards using statistical software (Microsoft Excel 2008, 
Microsoft Corporation, Redmond, WA, USA).  Each standard sample was run in duplicate.   
d.  Method validation 
The quantitative HPLC method for pioglitazone was validated by examining the 
measurement of consistency of results (within-run and between-run), correlation (coefficient of 
determination of the standard curve), and extraction efficiency of the assay.  The sample volume 
used for method validation was 200 µL.  The within-run precision was calculated from similar 
responses of six repeats of three control samples (10, 100, 400 ng) in one run.  The between-run 
precision was determined by comparing the calculated response (in ng/mL backfit of the 
standard curve) of the low (10 ng), middle (100 ng), and high (400 ng) control samples over 
three consecutive runs (total of six runs). The within-run and between-run accuracy was 
established by determining the ratio of calculated response to expected response for low (10 ng), 
middle (100 ng), and high (400 ng) control samples over six runs.  
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Standard curve correlation was measured by the mean coefficient of determination (r
2
) 
for six consecutive runs.  The extraction efficiency was determined by comparing the response 
(in area) of low (10 ng), middle (100 ng), and high (400 ng) standards, and the internal standard 
(250 ng), spiked into blank plasma eluent before evaporation, to the response from equivalent 
extracted standards.  The lower limit of detection (LOD) was calculated utilizing the analyte’s 
peak height compared to the baseline noise.  By this method, the LOD was defined as the lowest 
concentration of analyte producing a peak greater than or equal to three times the baseline noise 
of the chromatogram.  Additionally, the stability of pioglitazone (400 ng/200 L, n=4 for each 
experiment) in acetonitrile:water (50:50, v/v) stored at room temperature, in sample matrix 
refrigerated (4°C) for 2 and 4 weeks, and in sample matrix frozen (–20°C) for 2 and 4 weeks was 
investigated.  In this experiment, instrument responses from incubated samples were compared 
with those of freshly prepared samples using freshly prepared standard samples spiked with 
freshly prepared IS immediately before extraction.   
 Post-filtration IV samples of pioglitazone solution contained concentrations outside the 
range of the calibration curve.  These samples were diluted 1:100 with blank feline plasma 
before extraction.  Dilutional parallelism of the assay was confirmed by diluting duplicate 
samples of 1 mg/mL and 0.1 mg/mL pioglitazone 1:100 with blank feline plasma, and comparing 
assay results with expected concentrations.  Mean ± SD accuracy was 96 ± 0.3% and 99 ± 8.1% 
for low and high concentrations, respectively, and coefficient of variation for both was <1%.   
e. Pharmacokinetic and statistical analysis 
Pharmacokinetic analysis was carried out using commercially available software 
(Phoenix WinNonlin 6.1, Pharsight Corporation, Cary, NC, USA). IV data were best fit by a 
two-compartmental model, and oral data were analyzed using a noncompartmental model. 
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Pharmacokinetic parameters calculated following IV administration included area under the 
plasma concentration-time curve from time 0 to infinity (AUC0-inf), elimination half-life (t1/2k10), 
distribution half-life (t1/2α), terminal elimination half-life (t1/2ß), y-intercept for the distribution 
phase (A), y-intercept for the elimination phase (B), maximum plasma concentration (Cmax), 
systemic clearance (Cls), area under the moment curve from time 0 to infinity (AUMC0-inf), 
volume of distribution at steady state (Vss), volume of distribution of the central compartment 
(Vc), and volume of distribution of the terminal elimination phase (Vß).  Pharmacokinetic 
parameters calculated following oral administration included oral bioavailability (F), terminal 
elimination rate constant (λz), terminal elimination half-life (t1/2λz), area under the plasma 
concentration-time curve from time 0 to infinity (AUC0-inf), time to maximum plasma 
concentration (Tmax), maximum plasma concentration (Cmax), oral clearance (Cl/F), and mean 
residence time (MRT). 
Pharmacokinetic parameters from lean and obese cats were compared using a statistical 
software package (GraphPad Prism Version 5.00 for Windows, Graph Pad Software, San Diego, 
CA, USA).  A Kolgorov-Smirnov test was used to assess normality of the data, and an F-test was 
used to compare variances.  Those parameters that were normally distributed in both lean and 
obese cats were compared using an unpaired Student's t test with Welch's correction for unequal 
variances, if necessary; those with nonnormal distribution in either lean or obese cats were 
compared using a Mann-Whitney U test.  For all comparisons, hypothesis testing was two-tailed, 
and p-values less than 0.05 were considered significant.  
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3.4 Results 
 The HPLC diode array detection method reported here readily detects pioglitazone in 
plasma, with a LOD of approximately 2.5 ng/mL.  Mean ± SD extraction efficiency was 93 ± 
2.8%, 94 ± 6.0%, and 88 ± 5.0% at quantities of 10, 100, and 400 ng pioglitazone, respectively.   
Mean ± SD within-run accuracy was 99 ± 7.4%, 103 ± 7.4 %, and 104 ± 1.4 % for low, mid-
range, and high concentrations, respectively.  Corresponding coefficients of variation were 7.5, 
7.2, and 1.3%.   Mean ± SD between-run accuracy was 101 ± 5.4%, 104 ± 4.3%, and 101 ± 4.1% 
for low, mid-range, and high concentrations, respectively.  Corresponding coefficients of 
variation were 5.4, 4.1, and 4.0%.   
Results of HPLC analysis demonstrated 103 ± 1% (SD) recovery of pioglitazone stored 
in acetonitrile:water (50:50, v/v) at room remperature for 24 hr.  The stability of pioglitazone in 
feline plasma samples stored refrigerated and frozen (-20 °C) for 2 weeks was 104 ± 2% (SD) 
and 104 ± 4% (SD), respectively.  The stability of pioglitazone in feline plasma samples stored 
refrigerated and frozen (-20 °C) for 4 weeks was 108 ± 3.6% (SD) and 106 ± 6.9% (SD), 
respectively.   
Plasma concentration-time curves after IV administration of pioglitazone to lean and 
obese cats are shown in Figure 3.1.  Drug loss occurred during the final filtration step in the 
preparation of all IV pioglitazone solutions; as a result, the actual dosage of pioglitazone 
administered intravenously, as measured in post-filtration samples of prepared solution, ranged 
from 0.08-0.8 mg/kg, with a median of 0.17 mg/kg.   For comparison of the shapes of plasma 
concentration-time curves among individual cats and between lean and obese cats, 
concentrations obtained after IV administration were normalized to a dosage of 1 mg/kg.  
However, all data analysis, including calculation of pharmacokinetic parameters, was performed 
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using actual (measured) pioglitazone concentrations.  The latter procedures assume linearity of 
pioglitazone pharmacokinetics in cats; although this assumption has not been confirmed, linear 
pharmacokinetics have been demonstrated for pioglitazone in dogs at dosages of 0.1-3 mg/kg 
(Maeshiba, 1997), in rats at dosages of 0.5-30 mg/kg (Maeshiba, 1997), and in humans at doses 
of 7.5-45 mg (0.1-0.6 mg/kg for a 70 kg human, Eckland & Danhof, 2000).   Body weights at the 
time of IV administration, actual dosages of pioglitazone administered intravenously, and 
pharmacokinetic parameters after IV administration are shown for lean and obese cats in Tables 
3.1 and 3.2, respectively.     
 Plasma concentration-time curves after oral administration of pioglitazone to lean and 
obese cats are shown in Figure 3.2.  Oral administration of 3 mg/kg pioglitazone resulted in rapid 
absorption in 11/12 cats, although the extent of absorption was variable.  In one lean cat, 
pioglitazone was not detectable in plasma until 2 hours post-administration, after which 
concentrations increased to a peak at 12 h.  Measurement of concentrations was repeated on a 
different aliquot of the samples for verification, with the same result.  As this administration in 
this cat was considered an outlier, and as no data between 14 and 24 h were available for 
calculation of the terminal elimination half-life and AUC0-inf, oral pharmacokinetic parameters 
from this cat were not included in calculations of means or medians for statistical comparison.  
Body weights at the time of oral administration, actual dosages of pioglitazone administered 
orally, and pharmacokinetic parameters after oral administration are shown for lean and obese 
cats in Tables 3.3 and 3.4, respectively.     
 No significant difference was identified for any parameter between lean and obese cats.   
P-values for comparison of each parameter between lean and obese cats are shown for IV and 
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oral administration in Tables 3.5 and 3.6, respectively, as are mean ± standard deviation or 
median and range of pharmacokinetic parameters for all cats (lean and obese cats combined).    
 Dark red urine was noted in the litterbox of one obese cat after the cat received IV 
pioglitazone solution (4.6 mL solution; 0.18 mg/mL pioglitazone in DMSO).  The cat’s mucous 
membranes were pink, and attitude and clinical status remained within normal limits throughout 
the sample collection period.  No other abnormalities were noted in association with pioglitazone 
administration in any of the cats, or during subsequent daily observation of the pigmenturic cat.     
 
3.5 Discussion 
 The pharmacokinetics of pioglitazone have been characterized in rats, dogs, monkeys, 
and humans (Krieter et al., 1994; Maeshiba et al., 1997; Eckland & Danhof, 2000, Budde et al., 
2003; Kalliokoski et al., 2007) and have recently been described in horses (Wearn et al., 2010).  
Data regarding bioavailability, volume of distribution, and systemic clearance after IV 
administration are available from a single study in each species except the horse, in which only 
the oral form of the drug was given due to lack of a commercial IV formulation.      
 Mean bioavailability of pioglitazone in the cats of this study (approximately 55%) was 
lower than that reported for other species (85%, 94%, and 81%, and 83% in rats, dogs, monkeys, 
and humans, respectively (Maeshiba et al., 1997; Eckland & Danhof, 2000).  Bioavailability 
appeared to vary substantially among cats; however, a 95% confidence interval for the 
bioavailability data (45-67%) is similar in width to that reported for humans (74-93%; Eckland & 
Danhof, 2000).  Estimates of interindividual variation in the bioavailability of pioglitazone in 
other animals are not available, as reported bioavailability data for rats, dogs, and primates were 
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calculated from a mean dose and mean AUC0-inf of 3-5 animals of each species (Maeshiba et al., 
1997).   
 Differences in bioavailability of the same drug among individuals or groups can be 
caused by properties of the drug formulation, or by differences in physiological factors such as 
gastrointestinal transit time, pH of the gastrointestinal contents, intestinal transport proteins, and 
first-pass metabolism.  In the laboratory animals mentioned above, bioavailability data were 
generated using an oral solution of pioglitazone in citric acid.  This may account for the 
difference in bioavailability between these species and the cats studied here.  In humans, the 
marketed form of the drug is a rapidly disintegrating tablet, although bioequivalent encapsulated 
forms were used in some clinical studies (Xue et al., 2003).  Because dissolution, rather than 
disintegration, is the limiting step for absorption of most drugs from solid dosage forms 
(Baggott, 2001), the bioavailability of pioglitazone in rapidly disintegrating tablets and in the 
gelatin capsules used in this study is expected to be similar.  Thus, the lower mean bioavailability 
of the drug in cats compared to humans probably reflects the influence of various species-related 
physiologic factors.  Also, extent of absorption in cats dosed with the commercial tablet form of 
the drug is likely to approximate values reported in this study.   
 Absorption of orally administered pioglitazone was rapid in most cats, with a mean Tmax 
(3.6 h) similar to those of rats (4.0 ± 0.0 h), monkeys (4.3 ± 3.2 h), and humans (mean 1.5 or 2 h; 
range 0.5-3 h) (Maeshiba et al., 1997; Eckland & Danhof, 2000).  The high Tmax (12 h post-
administration) noted in a single lean cat was suspected to be due to retention of the capsule in 
the esophagus (despite administration with a small amount of canned food) or delayed gastric 
emptying, rather than an intrinsic difference in intestinal absorption.  In this cat, the shape of the 
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plasma concentration-time curve was not consistent with slow absorption over the entire dosing 
period, and Cmax was comparable to that of the other lean cats.   
 Other than the small amount of canned food given to facilitate dosing, animals in this 
study were fasted prior to drug administration and during the sample collection period.  In 
humans, administering pioglitazone in the fed state delayed absorption slightly (mean Tmax of 3-4 
h rather than 2 h), but did not affect the extent of absorption (Eckland & Danhof, 2000).   
 The volume of distribution at steady state (Vss) of pioglitazone after IV administration in 
cats (median 0.36 L/kg, range 0.27-0.63) is similar to the mean Vss in humans (0.25 ± 0.03 L/kg 
(EMEA 2004), rats, dogs, and monkeys (0.22 ± 0.005 L/kg, 0.47 ± 0.05 L/kg, and 0.31 ± 0.07 
L/kg, respectively (Maeshiba 1997).  In humans and rodents, pioglitazone is >97% bound to 
albumin, which limits its distribution outside the plasma compartment, despite its high 
lipophilicity (Eckland & Danhof, 2000).  Although the extent of plasma protein binding of 
pioglitazone in cats has not been studied, its median volume of distribution suggests that it also 
remains primarily in the plasma compartment in cats, and may also be highly protein-bound in 
this species.   
 Systemic clearance of pioglitazone in cats (mean 114 ± 37 mL/kg/h) is increased relative 
to systemic clearance in humans and rats (both approximately 60 mL/kg/h (Maeshiba et al., 
1997; Eckland & Danhof, 2000), and decreased relative to systemic clearance in dogs (329 ± 43 
mL/kg/h (Maeshiba et al., 1997).  In humans, pioglitazone is metabolized primarily by hepatic 
CYP2C8 and CYP3A4, with only a small amount of parent drug excreted in the urine (EMEA, 
2004).  At least three hydroxylated or oxidized metabolites (M-III, M-IV, and M-V) have been 
identified in human serum; of these, two (M-III and M-IV) possess pharmacological activity 
(Zhong & Williams, 1996; Eckland & Danhof, 2000). Hepatic metabolism of pioglitazone is also 
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the predominant mechanism of clearance in rodents, dogs, and monkeys (Maeshiba et al., 1997).  
However, major metabolites, their rates of formation, and their routes of excretion differ among 
species (Maeshiba et al., 1997; Shen et al., 2003).   
 In a study of the pharmacokinetics of troglitazone, a compound structurally similar to 
pioglitazone, in cats (Michels et al., 2000), no parent drug was detected in the urine of dosed cats 
over a 72-h period.  Based on these data and on the data from other species, it is probable that 
pioglitazone is metabolized by the liver in cats.  The current study did not provide any direct 
information about pathways of pioglitazone metabolism in the cat; no obvious metabolites were 
identified in HPLC analysis of samples from dosed animals.  This may have been a result of the 
fact that the HPLC methodology used was optimized for detection of parent drug, as was the 
assay in the above-referenced study of troglitazone (which also did not detect metabolites).  The 
reason for the increased clearance of pioglitazone in cats relative to humans, and decreased 
clearance in cats relative to dogs, is not clear at this time due to the paucity of information 
regarding pioglitazone metabolism in cats.  
 The mean oral elimination half-life (3.45 ± 0.93 h) for pioglitazone in the cats of this 
study is shorter than the mean 5.8 h (range: 3 to 9 h) reported for humans (Eckland & Danhof, 
2000), and than the mean 9.94 ± 4.57 h reported for horses (Wearn et al., 2010).  As a 
consequence, steady-state concentrations of pioglitazone in cats are likely to be achieved after a 
single administration.  In humans, the pharmacologically active metabolites of pioglitazone have 
significantly longer half-lives than the parent drug (26-28 h for M-III and M-IV (Eckland & 
Danhof, 2000)).  The same is true in rats, in which pioglitazone has a half-life of 2.6 h (Maeshiba 
et al., 1997), but produces a therapeutic effect when dosed every 24 hours (Ikeda et al., 1990; 
Sugiyama et al., 1990).  As discussed above, the metabolites of pioglitazone in cats and their 
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half-lives have not been studied, and the effects of pioglitazone, like those of the glucocorticoids, 
are mediated through changes in gene expression.  For these reasons, it is difficult to predict the 
impact of a shorter half-life for pioglitazone on the duration of its biological activity in cats. 
 The mean AUC0-inf (15556 ± 5556 ng/mL*h) achieved by administration of 3 mg/kg oral 
pioglitazone in the cats of this study is within the range of exposures associated with therapeutic 
efficacy in humans, and the mean Cmax (2131 ± 607 ng/mL) is slightly higher.  In humans, the 
therapeutic dose range is 15-45 mg; mean maximum plasma concentrations of pioglitazone in 
humans receiving doses of 15 and 45 mg have been reported to be 617±129 and 1552 ± 708 
ng/mL, respectively (Kalliokoski et al., 2007; Eckland & Danhof, 2000).  Areas under the 
plasma concentration-time curve for these doses were 6244 ± 1909 and 14071 ± 5727 ng/mL*h, 
respectively.  The exposure-response relationship for pioglitazone in rats is similar to the 
relationship in humans (Maeshiba et al., 1997; Ikeda et al., 1990).  Assuming that this is also true 
for cats, data from this study indicate that 1-3 mg/kg would be an appropriate oral dosage for 
efficacy assessment of pioglitazone in cats.   
 The safety of pioglitazone in cats after multiple dosing has not yet been evaluated, 
although no adverse effects were seen here after oral administration of a single 3 mg/kg dose of 
the drug.  Dark red urine was noted in one cat after IV administration of pioglitazone solution.  
As noted previously, pioglitazone is lipophilic and practically insoluble in water, and an IV 
formulation is not commercially available.  In pharmacokinetic studies using rodents, dogs, and 
monkeys, pioglitazone was dissolved in DMSO for IV administration (Maeshiba et al., 1997); in 
humans, it was dissolved in 30% propylene glycol and a maximum dose of 5 mg (0.07 mg/kg for 
a 70 kg human) was given as an infusion over 2 hours (Eckland & Danhof, 2000).  In the study 
reported here, pioglitazone was dissolved in a plasma:saline:DMSO solution for IV 
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administration.  This strategy had been previously employed in the study by Michels et al. 
involving the lipid-soluble drug troglitazone (Michels et al., 2000).  In that investigation, DMSO 
comprised 25% of the final solution by volume, and transient hemolysis was noted in the three 
cats to which the drug was given intravenously.  DMSO has been documented to cause 
hemolysis, hematuria, and methemoglobinemia in cats; severity increases with increased 
concentration of DMSO (DiStefano & Klahn, 1965).  The percentage of DMSO in the 
pioglitazone solution administered here was decreased to 10% in an attempt to avoid hemolysis.   
 No statistically significant differences were identified in the pharmacokinetic parameters 
for IV or oral pioglitazone between lean and obese cats.  Elimination half-life after oral 
administration tended to be shorter in lean cats, and this difference approached statistical 
significance.  As the sample size in this study was initially designed to detect differences in 
AUC0-inf, differences in half-life or other parameters may not have been apparent due to 
insufficient statistical power.  In humans, no direct comparisons of pharmacokinetic parameters 
for pioglitazone between lean and obese individuals have been published.  However, no obvious 
differences from healthy volunteers have been seen in the pharmacokinetics of pioglitazone in 
patients with type 2 diabetes, many of whom are obese, and no dosage adjustment is 
recommended for the drug in obesity (EMEA, 2004).   
 All the cats in this study were male.  Differences in the pharmacokinetics of pioglitazone 
between male and female rats have been reported; in a study by Fujita et al. (2003), mean Cmax , 
AUC0-inf, and t1/2 were increased by 20-50% in intact female rats.  A slightly increased Cmax and 
AUC0-inf for pioglitazone have also been seen in human females, but dose in these studies was 
not normalized for the lower body weight of the female subjects, and the differences were not 
considered to be clinically relevant (EMEA, 2004).       
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 In conclusion, pioglitazone is rapidly absorbed in cats after oral administration, with a 
mean bioavailability of 55%.  Volume of distribution of the drug after IV administration is 
similar to that seen in other species, while clearance is increased and half-life is decreased 
relative to humans.  Maximum plasma concentrations and total drug exposure, as measured by 
area under the plasma concentration-time curve, are variable after a 3 mg/kg oral administration, 
but approximate those associated with therapeutic efficacy in humans.  Further study will be 
necessary in order to establish an exposure-response relationship for pioglitazone in cats with 
insulin resistance and hepatic lipid accumulation, and to evaluate its efficacy in feline patients 
with type 2 diabetes mellitus or hepatic lipidosis.  
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3.6 Figures and Legends 
Figure 3.1 Mean plasma concentration (±SD) vs. time for lean (n=6) and obese (n=6) cats after 
IV administration of pioglitazone.  Concentrations were normalized to a dosage of 1 mg/kg.     
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Figure 3.2 Mean plasma concentration (±SD) vs. time for lean (n=5) and obese (n=6) cats after 
oral administration of 3 mg/kg pioglitazone.    
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Table 3.1  Pharmacokinetic parameters for pioglitazone following IV administration in lean cats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter 
Cat 1  Cat 2  Cat 3  Cat 4  Cat 5 Cat 6 
Mean ± SD, or 
median (range) 
Body weight (kg) 4.48 4.3 3.6 3.43 3.36 4.6 4.0 (3.4-4.6) 
Dosage (mg/kg) 0.84 0.16 0.09 0.09 0.14 0.18 0.15 (0.09-0.84) 
AUC0-inf (h*ng/ml) 4627 1319 841 1231 1211 2027 1876 ± 1402 
t1/2 k10 (h) 1.73 1.40 0.46 1.05 0.41 0.90 0.99 ± 0.52 
t1/2 α (h) 0.44 0.12 0.06 0.24 0.08 0.09 0.17 ± 0.15 
t1/2 ß (h) 2.64 2.18 2.32 2.97 2.56 3.07 2.62 ± 0.35 
A (ng/ml) 771 245 1049 570 1751 1145 910 (245-1751) 
B (ng/ml) 1087 406 224 242 276 425 341 (224-1087) 
Cmax (ng/ml) 1857 652 1273 812 2027 1570 1365 ± 556 
Cl (mL/kg/h) 182 123 102 73 113 90 113 ± 38 
AUMC h*h*ng/ml 16064 4009 2511 4512 3796 8353 6541 ± 5065 
MRT (h) 3.47 3.04 2.99 3.67 3.13 4.12 3.40 ± 0.44 
Vss (L/kg) 0.63 0.38 0.31 0.27 0.35 0.37 0.36 (0.27-0.63) 
V1 (L/kg) 0.45 0.25 0.07 0.11 0.07 0.12 0.18 ± 0.15 
V2 (L/kg) 0.18 0.13 0.24 0.16 0.29 0.25 0.21 ± 0.06 
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Table 3.2  Pharmacokinetic parameters for pioglitazone following IV administration in obese 
cats.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Cat 1  Cat 2  Cat 3  Cat 4  Cat 5  Cat 6  
Mean ± SD, or 
median (range) 
Body weight (kg) 6.6 5.53 6.25 6.7 6.85 6.64 6.4 (5.5-6.9) 
Dosage (mg/kg) 0.23 0.08 0.12 0.29 0.17 0.25 0.2 (0.08-0.29) 
AUC0-inf 
(h*ng/ml) 
1703 954 883 2920 2854 1484 
1800 ± 898 
t1/2 k10 (h) 1.13 1.30 0.96 0.84 1.68 0.82 1.12 ± 0.33 
t1/2 α (h) 0.16 0.12 0.12 0.13 0.25 0.09 0.14 ± 0.16 
t1/2 ß (h) 3.23 2.32 1.88 2.84 4.14 1.87 2.71 ± 0.88 
A (ng/ml) 720 235 336 1782 741 734 727 (235-1782) 
B (ng/ml) 329 273 303 628 434 515 382 (273-628) 
Cmax (ng/ml) 1048 508 639 2409 1175 1248 1171 ± 675 
Cl (mL/kg/h) 137 85 131 99 59 169 113 ± 40 
AUMC h*h*ng/ml 7190 3063 2250 10623 15548 3751 7071 ± 5193 
MRT (h) 4.22 3.21 2.55 3.64 5.45 2.53 3.60 ± 1.11 
Vss (L/kg) 0.58 0.27 0.33 0.36 0.32 0.43 0.35 (0.27-0.58) 
V1 (L/kg) 0.22 0.16 0.18 0.12 0.14 0.20 0.17 ± 0.03 
V2 (L/kg) 0.36 0.11 0.15 0.24 0.18 0.23 0.21 ± 0.09 
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Table 3.3  Pharmacokinetic parameters for pioglitazone following oral administration in lean 
cats.  NC= not calculated; *=not included in calculation of mean or median 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Cat 1  Cat 2  Cat 3  Cat 4  Cat 5  Cat 6*  
Mean ±SD, or 
median (range) 
Body weight 
(kg) 
4.56 4.25 3.6 3.47 3.39 4.58 3.98 ± 0.55 
Total dose 
(mg) 
15 12.9 10.8 10.4 10.6 13.7 12.2 ± 1.9 
Dosage 
(mg/kg) 
3.29 3.04 3.00 3.00 3.13 2.99 3.08 ± 0.05 
F (%) 86 63 49 52 46 NC 59 ± 16 
λ z (1/h) 0.27 0.27 0.25 0.18 0.26 NC 0.26 (0.18-0.27 
t1/2  λ z (h) 2.54 2.60 2.76 3.89 2.64 NC 2.64 (2.54-3.89) 
AUC0-inf 
(h*ng/ml) 
15906 15298 14500 21774 12821 NC 16060 ± 3398 
T max (h) 5 2 5 5 3 12 5 (2-5) 
Cmax (ng/ml) 2423 3012 2125 2625 2025 2301 2442 ± 398 
Cl_F (ml/kg/h) 207 198 207 138 244 NC 199 ± 38 
MRT (h) 7.41 4.71 6.42 8.70 5.92 NC 6.6 ±1.5 
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Table 3.4  Pharmacokinetic parameters for pioglitazone following oral administration in obese 
cats. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter 
Cat 1  Cat 2  Cat 3  Cat 4  Cat 5  Cat 6  Mean±SD, or 
median (range)  
Body weight 
(kg) 
6.6 5.5 6.35 6.6 6.67 6.72 6.6 (5.5-6.72) 
Total dose (mg) 19.7 16.7 19.1 19.9 19.9 20 19.2 ± 1.3 
Dosage (mg/kg) 2.98 3.04 3.01 3.02 2.98 2.98 3.00 ± 0.01 
F (%) 83 50 28 36 55 60 52 ± 19 
λ z (1/h) 0.21 0.13 0.22 0.20 0.14 0.20 0.20 (0.13-0.22) 
t1/2  λ z (h) 3.24 5.38 3.21 3.38 4.84 3.48 3.43 (3.21-5.38) 
AUC0-inf 
(h*ng/ml) 18037 17724 6404 10837 27102 10716 
15137 ± 7383 
T max (h) 3 4 3 4 4 2 3.5 (2-4) 
Cmax (ng/ml) 2223 1935 1112 1275 2918 1764 1871 ± 658 
Cl_F (ml/kg/h) 165 171 470 278 110 278 245 ± 129 
MRT (h) 6.57 9.56 6.01 7.18 9.40 5.73 7.4 ± 1.7 
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Table 3.5  P-values for comparison of pharmacokinetic parameters between lean and obese cats 
after single intravenous administration of pioglitazone, and mean ± SD or median (range) of each 
value for all cats.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter 
p-value (lean vs. obese) Mean ± SD, or median (range) 
for all cats 
Body weight (kg) 0.002 -- 
Dosage (mg/kg) 0.688 0.17 (0.08-0.84) 
AUC (h*ng/ml) 0.913 1838 ± 1123 
t1/2 K10 (h) 0.615 1.06 ± 0.42 
t1/2 α (h) 0.685 0.12 (0.06-0.44) 
t1/2 ß (h) 0.821 2.67 ± 0.64 
A (ng/ml) 0.485 840 ± 517 
B (ng/ml) 0.485 429 ± 240 
Cmax (ng/ml) 0.599 1268 ± 598 
Cl (mL/kg/h) 0.983 114 ± 37 
AUMC h*h*ng/ml 0.862 4261 (2250-16064) 
MRT (h) 0.696 3.5 ± 0.81 
Vss (L/kg) 
1.000 (Gaussian 
approximation) 
0.36 (0.27-0.63) 
V1 (L/kg) 0.514 0.17 ± 0.10 
V2 (L/kg) 0.501 0.21 ± 0.07 
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Table 3.6  P-values for comparison of pharmacokinetic parameters between lean and obese cats 
after single oral administration of pioglitazone, and mean ± SD or median (range) of each value 
for all cats.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter p-value (lean vs. obese) Mean±SD, or median (range)  
Body weight (kg) 0.002 -- 
Dosage (mg/kg) 0.195 3.00 (2.98-3.29) 
F (%) 0.527 55 ± 18 
λ z (1/h) 0.055 0.21 ± 0.05 
t1/2  λ z (h) 0.052 3.45 ± 0.93 
AUC (h*ng/ml) 0.792 15556 ± 5666 
T max (h) 0.351 3.64 ± 1.12 
Cmax (ng/ml) 0.125 2131 ± 607 
Cl_F (ml/kg/h) 0.432 224 ± 97 
MRT (h) 0.446 7.06 ± 1.6 
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Chapter IV 
 
 
 
 
Effects of pioglitazone on insulin sensitivity and serum lipids in obese, insulin-resistant cats 
 
 
 
 
4.1 Abstract 
 
Pioglitazone is a thiazolidinedione (TZD) insulin sensitizer approved for use in human 
type 2 diabetes mellitus.  In diabetic humans, this drug improves both glycemic control and lipid 
metabolism, and also has beneficial effects on pancreatic ß-cell function. The most common 
form of diabetes in cats, like type 2 diabetes in humans, is characterized by peripheral insulin 
resistance and insulin secretory defects; therapeutic options for this disease in cats are limited, 
and additional treatment choices would be beneficial.  The purpose of this project was to 
evaluate the metabolic effects of pioglitazone in obese, insulin-resistant cats, to assess its 
potential for future use in feline diabetes mellitus. Oral pioglitazone (Actos
TM
) was administered 
at 1 and 3 mg/kg to 12 obese cats, in a placebo-controlled 3-way crossover design.  Effects on 
insulin sensitivity, glucose clearance, and non-esterified fatty acid clearance were determined 
using intravenous glucose tolerance testing (IVGTT); additionally, effects on energy expenditure 
were measured via indirect calorimetry.  After 6 weeks of daily dosing, 3 mg/kg pioglitazone 
significantly improved insulin sensitivity, reduced insulin area under the curve during IVGTT, 
and lowered serum triglyceride and cholesterol concentrations in the obese cats.  No changes in 
energy expenditure were noted, and no adverse effects attributable to pioglitazone were evident 
in the otherwise healthy obese cats at this dosage and duration.  Results of this study support a 
positive effect of pioglitazone on insulin sensitivity and lipid metabolism in obese cats, and 
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suggest that further evaluation of the drug in cats with diabetes or other metabolic disorders may 
be warranted. 
 
4.2 Introduction 
Diabetes mellitus is a disorder of carbohydrate, lipid, and protein metabolism arising 
from absolute or relative insulin deficiency.  It occurs in 0.4-1% of domestic cats, and prevalence 
appears to be increasing (Prahl et al., 2007; McCann et al., 2007; Reusch, 2010). In humans, 
diabetes is classified as type 1 or type 2 based on etiopathogenesis; type 1 diabetes is 
characterized by absolute insulin deficiency and immune-mediated destruction of pancreatic ß-
cells, whereas type 2 involves a combination of insulin resistance and potentially reversible ß-
cell dysfunction. The most common form of diabetes in cats resembles human type 2 diabetes in 
several respects.  Specifically, emergence of clinical diabetes in cats depends on the balance 
between insulin sensitivity and ß-cell function (Nelson et al., 1999; Reusch, 2010; Hoenig, 
2012); as well, for both human type 2 and feline diabetes, obesity is a predisposing factor 
(Panciera et al., 1990; Buse et al., 2003).  
Obesity leads to insulin resistance in cats and humans (Buse et al., 2003; Hoenig et al., 
2007). In one study, insulin sensitivity in cats was estimated to decrease by 30% for each 1-kg 
increase in body weight (Hoenig et al., 2007). Impaired insulin sensitivity, from obesity or other 
causes, is accompanied by an increase in insulin secretion; this is referred to as compensatory 
hyperinsulinemia, and is an allostatic response that initially allows maintenance of normal blood 
glucose concentrations (Buse et al., 2003; Hoenig et al., 2011). In a subset of insulin-resistant 
cats, however, ß-cells are ultimately unable to sustain this high level of insulin production.  
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When insulin secretion becomes inadequate to overcome insulin resistance, overt diabetes 
develops (Hoenig et al., 2000).   
Current treatment options for feline diabetes are limited to insulin and the sulfonylureas. 
Although insulin is effective in many cases, it must be given by injection and carries the risk of 
hypoglycemia, both of which can be significant concerns for owners (Niessen et al., 2010). 
Sulfonylureas are insulin secretogogues that inhibit an ATP-dependent K
+
 channel on ß-cell 
membranes. Glipizide, a member of this drug class, has been used in diabetic cats; unfortunately, 
long-term treatment with glipizide promotes amyloid deposition in pancreatic islets, and does not 
enhance potential for β-cell recovery (Hoenig et al., 2000). A larger number of oral treatment 
choices for feline diabetes, particularly for owners unable or unwilling to attempt insulin therapy, 
would be beneficial.  
The thiazolidinediones (TZDs) are oral insulin sensitizers marketed for use in human type 
2 diabetes.  These drugs are agonists of the peroxisome proliferator activated receptor gamma 
(PPARγ), a nuclear transcription factor that is a key regulator of glucose metabolism, lipid 
metabolism, and adipogenesis (Lehmann et al., 1995; Tontonoz & Spiegelman, 2008). Treatment 
of humans and rodents with TZDs increases whole-body insulin sensitivity and promotes uptake 
and storage of circulating lipids by adipocytes (Yki-Järvinen, 2004); in type 2 diabetics, the 
result is improved glycemic control, reduced plasma lipid concentrations, and redistribution of 
lipids from sites of ectopic accumulation (muscle and liver) to adipose tissue (Aronoff et al., 
2000; Yki-Järvinen, 2004; Rasouli et al., 2005; Bajaj et al., 2010). Unlike sulfonylureas, TZDs 
have beneficial long-term effects on pancreatic ß-cells, increasing ß-cell sensitivity to glucose in 
human diabetics (Gastaldelli et al., 2007) and preserving islet structure in diabetic rodents (Diani 
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et al, 2004).  Also, as insulin sensitizers, they are associated with a low risk of hypoglycemia 
when used as monotherapy (DeFronzo, 2010). 
Because the TZDs are effective for type 2 diabetes in humans, they may prove useful for 
treatment of diabetes in cats. An experimental TZD, darglitazone, increased glucose and non-
esterified fatty acid (NEFA) clearance during glucose challenge in cats with obesity-induced 
insulin resistance (Hoenig & Ferguson, 2003). Darglitazone did not complete clinical 
development in either humans or animals; however, the TZD pioglitazone was approved for 
human use in 1999 and has remained commercially available (US FDA, 1999, Approval).  The 
purpose of this study was to evaluate the effects of pioglitazone in obese, insulin-resistant cats, in 
order to assess its potential for future use in feline diabetes mellitus.  We hypothesized that 
pioglitazone would increase insulin sensitivity and lead to enhanced glucose and lipid disposal in 
obese cats. 
 
4.3 Materials and Methods 
 Animals  
 Twelve Domestic Shorthair cats, six neutered males and six spayed females, 5-7 years of 
age, were used for this study.  At the beginning of the study, the cats weighed 5.4-9.8 kg (median 
6.2 kg), and were classified as obese based on gain of ≥50% of their adult lean body weight 
(median percent gain 99%; range 57-107%).  Obesity had originally been induced by ad libitum 
feeding, and all cats had been obese for >1 year. Cats were individually housed at the University 
of Illinois veterinary medical animal care facility, with free access to water, and were fed a 
commercial dry maintenance diet (Purina ProPlan Chicken and Rice
TM
, Nestlé Purina, St. Louis, 
MO, USA) once a day. Food intake was recorded daily and adjusted to maintain body weight, 
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which was recorded weekly. All study procedures were approved by the university's Institutional 
Animal Care and Use Committee and conducted in accordance with guidelines established by the 
Animal Welfare Act and the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals.  
 
Treatments 
      Cats were stratified by sex and percent gain of adult lean body weight, and randomly 
allocated to three treatment groups, either by drawing numbers from a box or by using a random 
number generator.  The same randomization method was used within each stratum. Each group 
contained 2 males and 2 females, and there were no statistically significant differences in median 
percent gain or body weight between groups.  A treatment sequence was assigned to each group 
using a random number generator.  Treatments consisted of seven weeks of placebo, 1 mg/kg 
oral pioglitazone, or 3 mg/kg oral pioglitazone, with each treatment followed by a seven-week 
washout period.  All cats received all treatments, in a 3-way crossover design.  Treatment 
sequences are shown in Table 4.1.  
  During each dosing period, pioglitazone (Actos
TM 
15 mg tablets, Takeda 
Pharmaceuticals America, Inc., Deerfield, IL, USA) or placebo was administered once daily, in 
the morning, with a small of canned food  (Hill’s a/dTM, Hill’s Pet Nutrition, Topeka, KS, USA, 
and Purina DM
TM
, Nestlé Purina, St. Louis, MO, USA).  Actos
TM
 tablets were divided using a 
pill cutter, weighed, and placed in gelatin capsules prior to administration.  Placebo capsules 
contained  186 mg powdered lactose (D-lactose monohydrate, USP-NF, Fisher Scientific, 
Pittsburgh, PA, USA), a quantity equivalent to the approximate amount of lactose in the greatest 
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number of pioglitazone tablets to be received by any cat during any period of the study.  Feeding 
of the daily ration was conducted without regard to the time of dosing. 
 
Physical examination, laboratory testing, and echocardiography  
Before each dosing period and during weeks 6-7 of dosing, a physical examination, 
complete blood count (CBC), biochemistry panel, and echocardiogram were performed on each 
cat. Total thyroid hormone (T4) was also measured prior to the first dosing period. 
Echocardiographic monitoring was elected based on data from preclinical toxicity studies of 
pioglitazone, in which hydrothorax and biventricular hypertrophy were noted after chronic 
dosing in some laboratory species (US FDA, 1999, Part 6).    
All laboratory testing was performed through the Clinical Pathology Laboratory at the 
University of Illinois College of Veterinary Medicine. Echocardiograms were performed by a 
board-certified veterinary radiologist at the University of Illinois College of Veterinary Medicine 
and included 2-dimensional screening for thoracic effusion or obvious atrial enlargement, as well 
as M-mode measurements of left ventricular posterior wall thickness in diastole (LVPWd), left 
ventricular internal diameter in systole and diastole (LVIDs, LVIDd), interventricular septal 
thickness in systole and diastole (IVSs, IVSd), % fractional shortening (FS), and left atrial/aortic 
(LA/Ao) ratio.  Respiratory rate, heart rate, and results of thoracic auscultation were recorded 
daily prior to dosing, and these data were evaluated visually during the dosing periods to identify 
trends in individual cats. 
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Indirect calorimetry 
For detection of any species-specific effects of pioglitazone on substrate metabolism or 
energy expenditure, indirect calorimetry was performed before each dosing period and during the 
6
th
 week of dosing.  Cats were fasted overnight and placed in 50 cm x 50 cm x 41 cm Plexiglass 
chambers connected to an open-circuit calorimetry system (Oxymax, Columbus Instruments, 
Columbus, OH).  The cats remained in the chambers for 8 hours, with free access to water 
throughout the experiment.  System flow rate was 5 L/min, settle time was 60 s, and measure 
time for each chamber was 30 s.  Calibration was performed daily using known calibration gas 
standards, and room temperature was maintained at 25 ± 1° C.  Basal heat production and 
respiratory exchange ratio were calculated according to the following equations: 
 
RER=liters CO2 produced  
          liters O2 consumed 
 
Heat production (kcal) = 3.82 x liters O2 consumed +1.15 x liters CO2 produced 
Heat production per metabolic body size (HMBS) = heat production (kcal/kg)/(body weight)
0.75 
 
Intravenous glucose tolerance testing  
    Intravenous glucose tolerance tests (IVGTTs) were performed immediately before each 
dosing period, and during the 7
th
 week of dosing.  At least 18 hours prior to IVGTT, cats were 
sedated with tiletamine/zolazepam (Telazol™, Fort Dodge, IA, USA; 2-4 mg/kg intramuscularly 
based upon tiletamine) to allow placement of jugular catheters (Intracath, Becton-Dickinson, 
Franklin Lakes, NJ, USA).  Catheter patency was maintained by flushing with sterile 0.38% 
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sodium citrate. After a 24-hour fast, a bolus of sterile 50% dextrose (0.8 g/kg) was administered 
intravenously, and samples were withdrawn from the jugular catheters at -5, 0 (immediately prior 
to dextrose administration), 5, 10, 15, 30, 45, 60, 90, 120, and 180 minutes.  Samples were 
placed in EDTA tubes on ice until centrifugation (1500 g for 10 minutes). Plasma was separated, 
aliquoted for measurement of glucose, insulin, NEFAs, and the adipocytokines adiponectin and 
leptin (time 0 only), and stored at –20 C.   
 
Pioglitazone concentrations 
   During each post-treatment IVGTT, selected samples from dosed animals were aliquoted for 
measurement of pioglitazone concentration.  On the same day, three additional samples were 
collected, such that plasma was available for pioglitazone measurement at 0h (predose), 2h, 3h, 
4h, 5h, 8h, and 11h after drug administration.  The additional samples were centrifuged and 
stored as described above. 
 
Assays 
Glucose was measured by a colorimetric glucose oxidase method (Glucose (Trinder) 
Assay, Genzyme Diagnostics, Charlottetown, PEI) and insulin by a porcine insulin 
radioimmunoassay with human insulin standards (Porcine Insulin RIA, Millipore, Billerica, MA, 
USA).  NEFAs were quantitated using an enzymatic colorimetric kit (NEFA-HR2, Wako 
Diagnostics, Richmond, PA, USA.)  Adiponectin was measured by ELISA (Human Adiponectin 
ELISA Kit, B-Bridge International, Inc., Sunnyvale, CA, USA), and leptin was measured by a 
commercial radioimmunoassay (Multispecies Leptin RIA kit, Linco, St. Charles, MO, USA). All 
samples were assayed in duplicate.  The adiponectin and leptin assays had been previously 
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validated in our laboratory for use in cats (Hoenig & Ferguson, 2002; Hoenig et al., 2007), and 
all samples were processed in the same assay. For the insulin assay, the standard curve for 
diluted feline samples was parallel to the curve for human insulin standards. Recovery of insulin 
from spiked samples in blank feline plasma was 103% at low and 94% at high concentrations.  
Inter-assay and intra-assay coefficients of variation were 6.3% and 11.9%, respectively. 
Pioglitazone concentrations were determined by high-perfomance liquid chromatography 
(HPLC), using a previously validated procedure (Clark et al., 2012).         
 
Data analysis 
 Baseline values for glucose, insulin, and NEFAs were calculated by taking the average of 
the measurements at -5 and 0 minutes of the IVGTT.  AUC0-180  for glucose and insulin 
concentrations, AUC00-90 and AUC 0-180 for NEFA concentrations and percent NEFA 
suppression, and coefficient of glucose disappearance (k) were calculated for each IVGTT using 
statistical software (GraphPad Prism Version 5.00 for Windows, Graph Pad Software, San 
Diego, CA, USA, or the R software package (Pinheiro et al., 2012)).  The AUC0-180  for glucose, 
NEFAs and insulin were calculated both in absolute terms and as delta AUC (AUC above or 
below baseline values), and percent NEFA suppression was calculated at each time point using 
the following formula: % suppression =100-(NEFA0/NEFAt) *100, where NEFA0 is NEFA 
concentration at baseline and NEFAt is NEFA concentration at time t after baseline.  Coefficient 
of glucose disappearance was calculated using the one-phase decay equation C=(C0 - Plateau)*e
(-
k*t)
 + Plateau, where C0 is extrapolated maximum glucose concentration at time 0, t is time, and 
Plateau is the value of C at infinite time.    
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Post-treatment body weights were obtained prior to the IVGTT (during week 6 of 
dosing), and  average daily food intake was calculated for each treatment period from day 1 of 
dosing to the day prior to indirect calorimetry (5-5.5 weeks of treatment) to avoid days when cats 
were fasted for assessments.  RER and heat production were calculated for each cat by taking the 
average of all measurements obtained over a 2-hour period (hours 4-6 of the experiment).  Cmax, 
AUC0-inf, terminal elimination half-life (t1/2), oral clearance (Cl/F), and oral volume of 
distribution (Vz/F) of pioglitazone for each cat were estimated from the concentration-time data 
using commercial software (Phoenix WinNonlin 6.1, Pharsight Corporation, Cary, NC, USA).   
The changes in basal and integrated glucose, NEFA, and insulin concentrations, 
integrated percent NEFA suppression, coefficient of glucose disappearance, body weight, 
adipocytokines, calorimetry data, clinical pathology values, and echocardiographic 
measurements were compared among treatments using linear mixed-effects modeling with 
logarithmic transformation of the data.  The factor “stage” was created to classify data as pre- or 
post-treatment for each period, and interactions of stage with treatment, period, and sequence 
were included in the regression model as fixed effects; when stage*period and stage*sequence 
were not significant, they were removed from the final model.  If a significant stage*sequence 
interaction was identified, its potential interference with the estimate of treatment effects was 
further evaluated using stage*treatment*sequence.  Variables with only one measure per period 
(pharmacokinetic parameters, food consumption, frequency of adverse events) were analyzed in 
a similar fashion, but fixed effects were treatment, period and sequence rather than interactions 
of these factors with the factor “stage”.  Cat and treatment within cat were included in the 
regression models as random effects.   
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Modeling was implemented in the R statistical software package (Pinheiro et al., 2012), 
with P-values <0.05 considered significant.   No correction for multiple comparisons was applied 
during analysis of clinicopathologic or echocardiographic data, since avoidance of Type II error 
(false negatives) rather than Type I error (false positives) was considered preferable in this 
circumstance.  Placebo was used as a reference for contrasts (except in the case of 
pharmacokinetic parameters); therefore, magnitudes of all reported changes with pioglitazone 
administration take into account the corresponding change with placebo administration.   
Insulin sensitivity, defined as the response of both glucose and NEFAs to endogenous 
insulin secreted during IVGTT, was quantified and compared among treatment groups as 
follows: 
 
Dynamic glucose-insulin data were analyzed by means of the minimal model (MM) of glucose 
disappearance (Bergman et al., 1979), which is described by the following differential equations 
 
Plasma glucose concentration, G(t), is the predicted model output that corresponds to an 
impulsive glucose administration of a known dose DG and with a given insulin concentration 
time course, I(t), viewed as known model input. Insulin acts on glucose disappearance through 
the delayed insulin action term X(t). Model parameters Gb and Ib are the measured basal glucose 
and insulin concentrations, respectively, and the remaining model parameters are estimated: SG 
(fractional glucose clearance at basal insulin); SI (insulin sensitivity of fractional glucose 
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disappearance); P2 (rate constant of time lag between supra-basal changes in insulin 
concentrations and insulin action, X(t)); and VG (apparent distribution volume).   
 
Dynamic NEFA-insulin data were analyzed by a reparameterized version of a previously 
proposed model of NEFA kinetics (Thomaseth & Pavan, 2005). The dynamic model equations 
resemble those of the MM, in particular the dynamics of insulin action, which in this case 
suppresses part of the circulating NEFAs. The model is defined as: 
 
 
where N(t) represents plasma NEFA concentration and XN(t), by analogy with insulin action X(t) 
in the MM, insulin action on NEFA suppression. The time-lag between supra basal changes in 
plasma insulin and NEFA suppression is characterized by the rate constant P2N.  NId and NIi 
represent insulin-dependent and insulin-independent NEFA concentrations at basal, respectively. 
The term │1- XN(t) │ 
+
   concisely describes the suppression of NEFA as a piece-wise linear 
function of insulin action XN(t). (The notation │x│
+
 represents the positive part of x, i.e. │x│+ = x 
if x > 0, and 0 otherwise).  Parameter SIN determines the slope of the suppression line, 1 - XN(t), 
as long as XN(t) < 1, as a function of deviations of insulin concentration from basal. The 
parameter SIN bears therefore the interpretation of sensitivity of fractional NEFA inhibition to 
changes in plasma insulin around basal. Unlike other proposed models of NEFA kinetics 
(Periwal et al., 2008), the present model is able to cope with insulin concentrations below basal 
by predicting an increase in NEFA concentrations. The present model defines therefore a finite, 
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non-zero insulin sensitivity of NEFA suppression around basal insulin and not only for positive 
increases as in Periwal et al (2008). 
Because the final NEFA concentration at 180 minutes was considerably higher than the 
concentration at the previous sample at time 120 min, the data considered for model fitting were 
restricted to the interval 0 to 120 minutes.  Regarding the identifiability of model parameters, the 
sampling during the initial NEFA decline was not sufficiently dense to allow the assessment of 
NEFA disappearance rate, under the hypothesis of complete inhibition of the insulin-dependent 
NEFA production. Moreover, the oscillatory pattern in the data during the first 15 minutes did 
not corroborate the expected first order elimination rate of NEFA under complete inhibition. For 
these reasons, it was assumed that NEFA clearance occurs with a half-life of 3 min (hence 
parameter kN was set to 0.231 min
-1
), and the 5 and 10 minute sample values were excluded from 
the final analysis.  
 
The MM parameters (SG, SI , P2, and VG), and the parameters of the NEFA kinetics model 
(NId, NIi, SIN, P2N) were estimated by fitting the two models to the corresponding glucose and 
NEFA concentrations, using in both cases the same measured insulin profile as model input. 
Parameter estimation was carried out using the statistical nonlinear mixed effects (NLME) 
modeling approach. From a population pharmacokinetic point of view, parameters were 
assumed log-normally distributed among the experiments performed in different cats or repeated 
in the same cats under different experimental conditions. The likelihood ratio test and Akaike's 
Information Criterion (AIC) were used to test significance of random effects to be included in 
the NLME model, whereas significance levels of fixed-effects parameter estimates was used as 
primary criterion for inclusion of a covariate into the regression model. The significance 
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level was set at 0.05.  
The effect of treatment on after - before differences in insulin sensitivity of glucose 
disappearance, SI , and in insulin sensitivity of NEFA suppression, SI N, was explicitly tested by 
including into the fixed effects regression model the interaction term stage * treatment. 
Stage*period and stage*sequence were also included, but were retained only when the 
corresponding parameter estimates were significant.  In the case of marginal significance, the 
likelihood ratio test and AIC were used as the primary criteria for decision between models 
including the interaction terms and those including only sequence and/or period in addition to 
stage*treatment.  All model identifications and parameter estimations were carried out using the 
nonlinear mixed effects package (Pinheiro et al., 2012). Mathematical model equations and 
simulation code were generated using the modeling software tool PANSYM (Thomaseth, 2003). 
 
4.4 Results 
Clinical observations, clinicopathologic data, and echocardiography      
     Throughout the study, no significant abnormalities were detected on physical 
examinations.  No differences were found among treatments in clinical pathology or 
echocardiographic measurements, with the exception of decreases in triglycerides (35% 
decrease; P=0.047), cholesterol (13% decrease; P=0.004), eosinophils (57% decrease; P=0.026), 
and phosphorus (8% decrease; P=0.018) with 3 mg/kg pioglitazone, and a decrease in cholesterol 
(9% decrease, P=0.034) with 1 mg/kg pioglitazone.  Values for these variables remained above 
the lower limit of the reference range in all cats.  Decreases in serum alkaline phosphatase (ALP) 
(9% decrease; P=0.024) and IVSs (12% decrease; P=0.014) were also noted after 3 mg/kg 
pioglitazone administration; however, for the changes in these variables, there was a significant 
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sequence effect, and because this effect was unequal among treatments (as indicated by the 
presence of a significant stage*treatment*sequence interaction), the contribution of pioglitazone 
administration could not be reliably determined.   
One or more episodes of vomiting occurred in 10/12 cats during the 8 months of the 
study. Vomiting was rarely temporally associated with drug administration (within 1 hour of 
dosing in <5% of occurrences), and was not associated with other clinical signs of illness.  The 
frequency was not significantly different for either dosage of drug vs. placebo (P=0.36 and 
P=0.76 for 1 and 3 mg/kg, respectively).  One cat died during sedation for catheter placement at 
the end of the last study period; necropsy and histopathology revealed myocardial fiber disarray 
characteristic of hypertrophic cardiomyopathy. 
 
Glucose and NEFA disposal 
 Pre- and post-treatment glucose, NEFA, and insulin concentrations vs. time during 
glucose tolerance testing are shown in Figures 4.1, 4.2, and 4.3, respectively.  Mean pre- and 
post-treatment fasting glucose, insulin and NEFA concentrations are shown in Table 4.2, and 
AUC 0-180 for glucose, insulin, and NEFAs, along with coefficient of glucose disappearance (k-
value), during the glucose tolerance test are shown in Table 4.3.   
There were no differences among treatments with respect to the change in fasting glucose 
or NEFA concentrations, absolute glucose AUC0-180, delta (above basal) glucose AUC0-180, or 
coefficient of glucose disappearance (k-value).  However, there was a significant decrease in 
insulin AUC0-180 with 3 mg/kg pioglitazone (34% decrease; P=0.003).  This difference was still 
present when insulin AUC0-180 was expressed as delta (above basal) AUC0-180 (44% decrease; 
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P=0.025).  Fasting insulin was also lower after 3 mg/kg pioglitazone, but the P-value for this 
change was at the borderline of significance (39% decrease; P=0.052). 
NEFA AUC0-180 decreased with 1 mg/kg pioglitazone (19% decrease; P=0.021) but not 
with 3 mg/kg pioglitazone (P=0.29). When NEFA AUC0-180 was expressed as delta (below basal) 
NEFA concentration, the decrease with 1 mg/kg treatment was no longer significant (P=0.12).  
This suggested that it was dependent on trends in the baseline values (although, as mentioned 
above, changes in these fasting baseline values were not significantly different for either dose of 
drug vs. placebo). Plotting the NEFA concentrations as percent suppression from baseline 
revealed a subjectively greater initial suppression, and an earlier, more precipitous rebound from 
suppression, as the dosage increased (Figure 4.4).  The steeper rebound for pioglitazone vs. 
placebo was also evident in the absolute NEFA concentration vs. time profiles (Figure 4.3).  
 Because of the pattern observed in the NEFA profiles, AUC for percent NEFA 
suppression was calculated both as AUC0-180 (total NEFA suppression) and as AUC0-90 (initial 
NEFA suppression, excluding the rebound phase) (Table 4.3). AUC0-180 for percent NEFA 
suppression increased by 33% (P=0.036) with 1 mg/kg pioglitazone, but the change with the 3 
mg/kg dosage was not significant (P=0.26).  In the case of AUC0-90 for percent NEFA 
suppression, however, there was an increase with both 1 and 3 mg/kg pioglitazone (43% 
increase, P=0.025, and 36% increase, P=0.048, respectively).  AUC0-90 was also calculated for 
absolute NEFA concentrations (Table 4.4).  The results for NEFA AUC0-90 were similar to those 
for NEFA AUC0-180 for 1 mg/kg pioglitazone (23% decrease; P=0.031); for 3 mg/kg 
pioglitazone, the change in NEFA AUC0-90 was at the borderline of significance (21% decrease, 
P=0.053).   
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For all calculations involving AUC for percent NEFA suppression, it was necessary to 
eliminate two profiles with an average suprabasal NEFA increment from analysis, as they 
yielded negative AUCs that were not amenable to log transformation.  Because one of these 
profiles occurred after placebo, and one after 1 mg/kg pioglitazone, their exclusion had the 
potential to artificially improve the measures of percent NEFA suppression for both placebo and 
the 1 mg/kg dosage.  Therefore, although the validity of the changes in percent NEFA 
suppression with 1 mg/kg pioglitazone vs. placebo is questionable, the increase in AUC0-90 for 
percent NEFA suppression with 3 mg/kg pioglitazone vs. placebo may actually have been greater 
than reported.    
 
Insulin sensitivity 
Insulin sensitivity of glucose disposal, SI, increased by 141% after treatment with 3 
mg/kg pioglitazone (P=0.0014). Administration of 1 mg/kg pioglitazone increased SI by 46%, 
but this difference was not statistically significant (P=0.15).  Insulin sensitivity of NEFA 
suppression, SIN, increased by 108% with 3 mg/kg pioglitazone (P=0.014).  The change with 1 
mg/kg pioglitazone was not significant (35% increase; P=0.37).  Average best fit of the NEFA 
kinetic model to measured NEFA concentrations is shown in Figure 4.5.  
 
Adipokines 
     Mean pre- and post-treatment values for adiponectin and leptin are shown in Table 4.2.   
Adiponectin concentration increased by 127% (P=0.0024) after 1 mg/kg pioglitazone treatment, 
and by 289% (P<0.0001) after 3 mg/kg pioglitazone treatment.  There was no effect of 
pioglitazone on plasma leptin concentration. 
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Energy expenditure, body weight, food intake, and substrate metabolism 
 Pre- and post-treatment values for body weight, average daily food intake, RER, heat 
production (kcal/h), and heat production per metabolic body size (kcal/h/kg) are shown in Table 
4.4.  There was a statistically significant but very small decrease in mean RER after treatment 
with both 1 and 3 mg/kg pioglitazone (1.5% decrease, P=0.014, and 1.3% decrease, P=0.036, 
respectively).  There were no differences among treatments for changes in the other variables.  
 
 
Plasma pioglitazone concentrations 
  Plasma concentration-time profiles for 1 and 3 mg/kg administration of oral 
pioglitazone are shown in Figure 4.6.  Mean ± SD Cmax, AUC0-inf , and terminal elimination half-
life estimated by noncompartmental analysis of concentration-time profiles are displayed in 
Table 4.5.   
Mean Cmax and AUC0-inf for pioglitazone were greater after 3 mg/kg than after 1 mg/kg 
administration (P≤0.001), as expected, although the increases were less than proportional. There 
was no difference in mean terminal elimination half-life between dosages (P=0.997). However, 
mean oral clearance (Cl/F) and apparent volume of distribution (Vz/F) were higher after 3 mg/kg 
than after 1 mg/kg administration (for Cl/F, mean ± SD 297 ± 111 vs. 155 ± 58 mL/kg/h, 
P<0.001; for Vz/F, 1.5 ± 0.51 vs. 0.78 ± 0.25 L/kg, P=0.003). 
Trough pioglitazone concentration (pre-dose time point; 22-23h after the last dose) was 
below the LLOQ of the assay for 10/11 1 mg/kg administrations and for 7/11 3 mg/kg 
administrations.  The maximum trough plasma concentration for any cat was 42 ng/mL for 1 
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mg/kg pioglitazone and 68 ng/mL for 3 mg/kg pioglitazone, indicating minimal accumulation of 
parent drug after chronic administration. 
 
4.5 Discussion 
The insulin-sensitizing properties of pioglitazone have been well described in obese and 
type 2 diabetic humans, and results of this placebo-controlled study demonstrate that 
pioglitazone, at 3 mg/kg, increases insulin sensitivity in obese cats.  Improved insulin sensitivity 
was suggested by the significant decrease in AUC for insulin and the lack of an increase in AUC 
for glucose or NEFAs during IVGTT in view of lower insulin concentrations.  Additionally, it 
was confirmed for both glucose and NEFA concentrations using an approach based on the 
minimal model of glucose kinetics. The insulin sensitivity index (SI) generated by the minimal 
model reflects the actions of insulin to stimulate peripheral glucose uptake and suppress hepatic 
glucose production, whereas its counterpart (SIN) in the corresponding NEFA model describes 
the potency of insulin to promote fatty acid uptake and inhibit peripheral lipolysis.  The dual 
improvement in these indices in the obese cats is consistent with findings in other species that 
pioglitazone amplifies insulin signaling in multiple organs, including muscle, adipose tissue, and 
the liver (Sugiyama et al., 1990; Hofmann & Colca, 1992; Bajaj et al., 2004; Yki-Järvinen, 
2004).    
The improvement in insulin sensitivity with pioglitazone was less than that observed with 
the experimental TZD darglitazone (Hoenig & Ferguson, 2003), which can be explained by the 
difference in potency between these two agents (Day et al., 1999; Aleo et al., 2003).  However, 
the impact of insulin sensitization with pioglitazone was still evident from several changes that 
occurred during IVGTT. First, the decrease in insulin AUC represents the β-cell response to 
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increased insulin sensitivity, and reflects reduced secretory demand and lessening of the stimulus 
for compensatory hyperinsulinemia.  Alleviation of compensatory hyperinsulinemia was also 
present after darglitazone administration in obese cats (Hoenig & Ferguson, 2003), and is a 
predictable outcome of TZD administration in obese, insulin-resistant humans and rodents (Ikeda 
et al., 1990; Nolan et al., 1994; Powell et al., 2012).  Because chronic ß-cell overstimulation is 
associated with increased amyloid deposition in diabetic cats (Hoenig et al., 2000), the lower 
secretory demand posed by pioglitazone may offer benefits in terms of ß-cell function and 
survival.  In transgenic mice expressing human islet amyloid polypeptide, both the TZD 
rosiglitazone and another insulin sensitizer, metformin, decreased the severity of amyloid 
deposition in conjunction with limiting ß-cell apoptosis (Hull et al., 2005).   
Second, 3 mg/kg pioglitazone enhanced NEFA suppression during the first 90 minutes of 
IVGTT.  Potential mechanisms for this change include decreased NEFA release (due to greater 
inhibition of lipolysis), increased NEFA uptake, or some combination of the two.  In obese 
Zucker rats, in which the actions of TZDs on NEFA metabolism have been studied in detail, 
TZDs enhance both lipolytic inhibition and NEFA uptake under insulin-stimulated conditions. 
This leads to a net flux of NEFAs into peripheral adipose depots and a corresponding depletion 
of ectopic lipid from other tissues, as the majority of the NEFA uptake is into adipocytes (Oakes 
et al., 2001).  Consequently, TZD treatment in Zucker rats is associated with a decrease in the 
triglyceride content of muscle, liver, and pancreatic ß-cells (Shimabukuro et al., 1998; Hockings 
et al., 2003).  Similar effects in terms of both lipolytic inhibition and muscle and liver 
triglyceride occur in pioglitazone-treated humans (Ravikumar et al., 2008; Gastaldelli et al., 
2009; Bajaj et al., 2010).  Thus, it might be postulated that preferential adipose tissue NEFA 
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uptake and lipolytic inhibition were components of NEFA suppression in the obese cats, 
although this would require further study for confirmation.   
An interesting feature of the post-pioglitazone NEFA profiles in the obese cats was the 
brisk suprabasal rebound that followed initial suppression. In people, this has been attributed to 
lipolytic hormone release secondary to rapid glucose clearance, and is faster in lean than in obese 
individuals (Bolinger et al., 1962; Prando, Cordera, DeMicheli et al., 1978; Prando, Cordera, 
Odetti et al., 1978). A similar phenomenon has been described after pharmacological doses of 
glucose administered orally, and the magnitude of the NEFA rebound in one study was 
positively correlated with insulin sensitivity (Fernandes et al., 2012). The subjectively steeper 
rebound with pioglitazone in the cats, therefore, appears compatible with a return to a more 
insulin-sensitive state, and may actually reflect a biologically significant increase in glucose 
clearance.  Based on the lack of a concurrent change in glucose AUC or k-value, this possible 
effect of pioglitazone on glucose clearance was more subtle than its effects on NEFA 
metabolism, which may seem surprising considering the slightly greater change in SI than in SIN.  
A potential explanation is that peripheral lipolysis is inherently more responsive to insulin than is 
glucose uptake (Zierler & Rabinowitz, 1964; Yki-Järvinen et al., 1987); thus, a comparable 
increase in the insulin sensitivity of both processes will be manifest to a greater degree in NEFA 
than in glucose dynamics.     
In general, the effects of TZDs on glucose and NEFAs are more pronounced in diabetic 
than in obese humans and rodents, and even among non-diabetic humans with impaired glucose 
tolerance, the glycemic effects of TZDs are greatest in those with the highest initial glucose 
concentrations (Nolan et al., 1994; Frias et al., 2000; Powell et al., 2012). This is distinct from 
results observed with administration of sulfonylureas to non-diabetic subjects (Unger & 
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Madison, 1958; Groop et al., 1987), and is a consequence of the fact that TZDs improve the 
tissue response to insulin without disrupting endogenous glucose-insulin feedback.  Thus, given 
its effects on insulin sensitivity in obese cats, pioglitazone may favorably affect glycemic control 
in diabetic cats. Also, in light of its effect on NEFA suppression in obese cats, it may improve 
NEFA metabolism in diabetic cats and reduce complications such as hepatic lipid accumulation. 
One caveat with regard to these hypotheses, however, is that TZDs are clinically ineffective in 
the absence of insulin (Ikeda et al., 1990; Day et al., 1999). Therefore, although the insulin-
sensitizing actions of pioglitazone in the obese cats are encouraging in terms of its therapeutic 
potential, effects in diabetic cats remain speculative and would depend on insulin secretory 
capacity, which has been shown to be low in some diabetic cats (Crenshaw & Peterson, 1996; 
Nelson et al., 1999).   
The changes in serum lipids that occurred with pioglitazone in the obese cats are 
comparable in some respects to those that occur in pioglitazone-treated humans.  Insulin 
resistance in humans, rodents, and cats is associated with dyslipidemia characterized by an 
increased mass of triglyceride (TG) in very low-density lipoproteins (VLDL), coupled with 
decreases in low-density lipoprotein (LDL) particle size and high-density lipoprotein (HDL) 
particle size and concentration (Ginsberg et al., 2005; Jordan et al., 2008). In diabetic humans 
and Wistar fatty rats, pioglitazone lowers triglyceride concentrations by increasing the clearance 
of VLDL-TG from circulation; this is thought to occur through an increase in the activity of 
lipoprotein lipase (LPL), an insulin-regulated enzyme that mediates VLDL-TG hydrolysis 
(Kazumi et al., 1996; Nagashima et al., 2005).  A similar mechanism may have been responsible 
for the decrease in triglycerides in the obese cats.  
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With regard to cholesterol, the effects of pioglitazone in humans differ slightly from 
those observed in the obese cats; pioglitazone increases HDL cholesterol in obese or diabetic 
humans, but generally does not change total cholesterol concentration (Nagashima et al., 2005; 
Szapary et al., 2006; Powell et al., 2012).  This difference between humans and cats may relate to 
the fact that 1) cats, unlike humans, carry most of their cholesterol in HDL, and 2) activity of 
cholesteryl ester transfer protein (CETP), which catalyzes the exchange of triglycerides and 
cholesterol between HDL and other lipoproteins, appears to be very low in cats (Watson, 1996). 
Rodents share both of these characteristics of cholesterol metabolism with cats (Hogarth et al., 
2003), and pioglitazone does reduce total cholesterol in obese and diabetic rats (Mizushige et al., 
2002; Wallis et al., 2004; Hirasawa et al., 2008).  Since islet cholesterol homeostasis is now 
recognized as an important regulatory factor in glucose-stimulated insulin secretion (Hao et al., 
2007; Kruit et al., 2010), and since hypercholesterolemia has been identified as a negative 
predictor of diabetic remission in cats (Zini et al., 2010), it is possible that the cholesterol-
lowering effect of pioglitazone, as observed in the obese cats, would ultimately impart clinical 
benefit in diabetic cats. Furthermore, the effects of pioglitazone on both triglycerides and 
cholesterol, as well as its influence on NEFA suppression, may eventually prove useful in cats 
with other dyslipidemias.  Cats with idiopathic hepatic lipidosis have increased triglyceride 
content in all lipoproteins, and elevated NEFA concentrations due to excessive peripheral 
lipolysis (Pazak et al., 1998).  Depending on the role of insulin resistance in feline hepatic 
lipidosis, pioglitazone administration could theoretically lead to improved lipid metabolism and 
mobilization of hepatic triglyceride in this disorder.   
Although most other outcomes of pioglitazone administration were significant only at the 
3 mg/kg dosage, even 1 mg/kg pioglitazone in the obese cats caused a robust increase in plasma 
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concentrations of adiponectin. Adiponectin is an adipose-derived cytokine with insulin-
sensitizing, anti-apoptotic, and anti-inflammatory effects, and because its secretion decreases 
with increasing fat mass and insulin resistance, concentrations are abnormally low in obese and 
diabetic humans and cats (Yu et al., 2002; Hoenig, 2006; Hoenig et al., 2007; Turer & Scherer, 
2012). The relevance of the increase in adiponectin with pioglitazone is twofold.  First, it 
signifies activation of PPARγ, the molecular target of the TZDs; TZDs directly increase 
adiponectin expression through a PPARγ response element in the adiponectin promoter, and a 
dose-dependent increase in this cytokine is a reliable sequel of PPARγ agonist administration in 
humans and rodents (Maeda et al., 2001; Yu et al., 2002; Iwaki et al., 2003).  Second, 
adiponectin is a possible mediator of the effects of pioglitazone on insulin sensitivity. It is 
required for the hepatic insulin-sensitizing actions of pioglitazone in genetically obese and 
hyperglycemic ob/ob mice (Kubota et al., 2006).  As well, it appears to have insulin-sensitizing 
effects on muscle glucose uptake, hepatic glucose production, and lipoprotein metabolism in 
humans (Tschritter et al., 2003; Bajaj et al., 2004; Hulstrom et al., 2008). 
In the cats of this study, pioglitazone produced no change in energy expenditure or mean 
body weight, and the small decreases in respiratory exchange ratio identified during indirect 
calorimetry are unlikely to be biologically significant.  The effects of pioglitazone on energy 
expenditure were of interest because TZDs have been associated with weight gain in humans and 
rodents (Festuccia et al., 2008; Barnett, 2009).  This has been ascribed to the adipogenic 
activities of PPARγ; however, as some investigators have pointed out (Ryan et al., 2011), an 
increase in adipogenesis will not produce weight gain unless it is supplemented by an increase in 
food intake or a decrease in energy expenditure. In normal rats, both a decrease in energy 
expenditure and an increase in food intake are seen with TZD administration, with the former 
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resulting from a drug-induced downregulation of sympathetic outflow and thyroid status 
(Festuccia et al., 2008).  In contrast, pioglitazone does not alter energy expenditure in obese, 
diabetic humans, consistent with its effects in the obese cats (Smith et al., 2005).  Also, the lack 
of a change in body weight in the cats, which were fed a fixed ration, is similar to reports in 
humans that weight gain did not occur when pioglitazone was administered with a portion 
controlled-diet (Martin et al., 2010).  
In addition to weight gain, the adverse effects profile of pioglitazone in humans includes 
fluid accumulation (manifest as peripheral edema or, more rarely, congestive heart failure), mild, 
reversible decreases in red blood cell count, increased risk of distal limb fractures in 
postmenopausal women, and possible increased risk of bladder cancer with long-term use (>2 y) 
(Barnett et al., 2009; Loke et al., 2009; Lewis et al., 2011). Red blood cell decrement and fluid 
accumulation were also observed in mice, rats, dogs, and monkeys during preclinical testing (US 
FDA, 1999, Part 1; US FDA, 1999, Part 2; EMEA, 2004), and cardiac hypertrophy and thoracic 
effusion occurred in some of these laboratory animals at ≥5 times the human exposure and/or 
after durations of ≥1 year (US FDA, 1999, Part 1; US FDA, 1999, Part 6).  These changes were 
considered to be a response to chronic volume overload rather than a result of direct cardiac 
toxicity (US FDA, 1999, Part 1; US FDA, 1999, Part 2).   
In view of these potential adverse effects, cats in this study were monitored by physical 
examination, laboratory evaluation, and echocardiography. All cats appeared healthy prior to 
study entry based on these criteria; however, despite normal echocardiographic findings, one cat 
experienced cardiac arrest under sedation and had myofiber disarray typical of hypertrophic 
cardiomyopathy (HCM) at necropsy. This histologic abnormality is unlikely to have been caused 
by short-term pioglitazone administration, although exacerbation of pre-existing disease cannot 
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be ruled out.  In the other obese cats, pioglitazone did not cause echocardiographic changes or 
clinical signs of toxicity when administered at 1 or 3 mg/kg for 6 weeks, and most laboratory 
parameters, including red blood cell count, were unaffected by pioglitazone at this dosage and 
duration.  The clinical significance of the observed decreases in eosinophils and serum 
phosphorus is unclear, as such changes do not appear to have been reported with pioglitazone in 
other species, and neither variable fell below the reference range in any cat. Mild decreases in 
total white blood cell count have been observed with TZDs in some studies in obese humans, in 
association with decreases in other markers of systemic inflammation, but in these investigations, 
no reductions in specific leukocyte fractions were found to be responsible (Ghanim et al., 2006; 
Szapary et al., 2006).   
The dosages of pioglitazone used in this study were selected based on a previous 
pharmacokinetic evaluation, and were designed to bracket the range of human therapeutic 
concentrations (Clark et al., 2012). Pioglitazone concentrations were measured after dosing in 
order to verify drug exposure, establish a concentration-response relationship, and detect changes 
in pharmacokinetics with chronic administration. Cmax and AUC0-inf, as assessed by limited 
sampling, were similar to concentrations achieved previously in cats (Clark et al., 2012) and to 
concentrations considered therapeutic in humans (Eckland & Danhof, 2000; Kalliokoski et al., 
2007), but increases in these parameters between dosages were less than proportional.   
Subproportional increases in Cmax and AUC0-inf have also been reported for pioglitazone in dogs, 
rodents, and diabetic humans, at dosages ranging from approximately 1 to 100 mg/kg (EMEA, 
2004; US FDA, 1999, Part 1).  
Either changes in bioavailability or changes in elimination with increasing dose may 
account for lack of dose proportionality.  In the cats of this study, half-life was not different 
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between dosages, and was similar to values obtained previously after single oral and IV doses in 
cats (Clark et al., 2012; Chapter 3).  However, estimates of oral clearance (Cl/F) and apparent 
volume of distribution (Vz/F) were approximately doubled after 3 mg/kg compared with 1 mg/kg 
administration.  Half-life is affected by both clearance and volume of distribution, with greater 
clearance tending to decrease half-life and a greater volume of distribution tending to increase it. 
Although equivalent increases in Cl and Vz could theoretically have occurred with 3 mg/kg 
administration, leaving half-life unchanged, a more likely explanation for the changes in Cl/F 
and Vz/F is a relative decrease in oral bioavailability (F) at the higher dosage.  This is also 
suggested by the lower Cmax with 3 mg/kg administration; a change in elimination rate alone 
would be likely to change AUC0-inf without necessarily altering Cmax.  Comparison of the median 
doses and mean AUCs obtained here with those calculated in obese cats after a single IV dose 
yielded oral bioavailabilities of 84% and 47%, respectively, for 1 and 3 mg/kg pioglitazone.  
These estimates must be interpreted with caution due to the different study population and 
sampling schedule used to generate the IV data, and the use of mean and median parameters 
rather than individual values. Nonetheless, the apparent dose-dependent absorption 
characteristics of pioglitazone in cats, as suggested by the data presented here, may explain the 
fact that the absolute bioavailability calculated previously after a single 3 mg/kg oral dose (Clark 
et al., 2012) was lower than that reported with therapeutic dosages of pioglitazone in humans.   
Although NEFA concentrations as a percentage of baseline appeared to increase after 
placebo dosing, no biological explanations for this observation are evident.  The amount of 
powdered lactose in the placebo capsules was very small, and no reports of an effect of orally 
administered lactose on NEFA concentrations could be located in the literature.  Regardless of 
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the cause, any change in the placebo group is not likely to have impacted study conclusions, as 
all comparisons were made using the placebo group as a reference.  
In summary, oral pioglitazone (Actos
TM
) significantly improved insulin sensitivity and 
lowered plasma cholesterol and triglyceride concentrations in obese, insulin-resistant cats, after 6 
weeks of daily dosing at 3 mg/kg.  No changes in energy expenditure were noted, and no overt 
clinical toxicity attributable to pioglitazone was evident in otherwise healthy obese cats at this 
dosage and duration.  Based on these results, further investigation of pioglitazone in diabetic 
cats, or in cats with other lipid metabolic disorders, may be warranted. 
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4.6 Figures and Legends 
Figure 4.1 Glucose concentrations (mean ± SEM) vs. time during IVGTT in obese cats (n=11-
12) before and after 6 weeks of administration of placebo, 1 mg/kg oral pioglitazone, or 3 mg/kg 
oral pioglitazone.  
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Figure 4.2  Insulin concentrations (mean ± SEM) vs. time during IVGTT in obese cats (n=11-
12) before and after 6 weeks of administration of placebo, 1 mg/kg oral pioglitazone, or 3 mg/kg 
oral pioglitazone. 
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Figure 4.3  Non-esterified fatty acid (NEFA) concentrations (mean ± SEM) vs. time during 
IVGTT in obese cats (n=11-12) before and after 6 weeks of administration of placebo, 1 mg/kg 
oral pioglitazone, or 3 mg/kg oral pioglitazone. 
 
0 50 100 150 200
0.0
0.2
0.4
0.6
0.8
Placebo before
Placebo after
Time (min)
N
E
F
A
 (
m
E
q
/L
)
0 50 100 150 200
0.0
0.2
0.4
0.6
0.8
1 mg/kg before
1 mg/kg after
Time (min)
N
E
F
A
 (
m
E
q
/L
)
0 50 100 150 200
0.0
0.2
0.4
0.6
0.8
3 mg/kg before
3 mg/kg after
Time (min)
N
E
F
A
 (
m
E
q
/L
)
 
 
 
 
 
 
109 
 
Figure 4.4  Percent suppression of non-esterified fatty acid (NEFA) concentrations (mean ± 
SEM) vs. time during IVGTT in obese cats (n=11-12) before and after 6 weeks of administration 
of placebo, 1 mg/kg oral pioglitazone, or 3 mg/kg oral pioglitazone. 
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Figure 4.5  Average best fit of the non-esterified fatty acid (NEFA) kinetic model used to 
determine insulin sensitivity of NEFA suppression (SIN) to NEFA concentrations measured 
during IVGTT in obese cats (n=11-12).  
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Figure 4.6  Pioglitazone concentrations (mean ± SEM) vs. time after 6 weeks of administration 
of 1 or 3 mg/kg oral pioglitazone (Actos
TM
) to obese cats (n=11-12).  Note logarithmic y-axis.    
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Table 4.1  Treatment sequences used in the 3-way crossover design for assessing the effects of 
two dosages of oral pioglitazone vs. placebo in obese cats.  Each dosing period was separated 
from the next by a 7-week washout period.    
 
 Period 1 Period 2 Period 3 
Sequence 1 Placebo 3 mg/kg 1 mg/kg 
Sequence 2 1 mg/kg Placebo 3 mg/kg 
Sequence 3 3 mg/kg 1 mg/kg Placebo 
 
 
 
 
Table 4.2. Fasting glucose, insulin, NEFA, and adipocytokine concentrations in 12 obese cats 
before and after 6 weeks of treatment with placebo, 1 mg/kg pioglitazone, or 3 mg/kg 
pioglitazone.  Values with non-normal distribution are expressed as median (IQR); normally 
distributed values are expressed as mean ± SE. *= significant change from pre-treatment value 
vs. change with placebo (P<0.05).  
 
  Placebo 1 mg/kg pioglitazone 3 mg/kg pioglitazone 
Glucose, baseline 
(mmol/L) 
Pre 4.8 (4.3-5.2) 4.7 (4.3-5.7) 4.8 (4.3-5.2) 
Post 4.3 (4.1-4.5) 4.2 (4.2-4.4) 4.3 (3.9-4.8) 
Insulin, baseline 
(pmol/L) 
 
Pre 66 (44-83) 76 (29-90) 47 (28-116) 
Post 42 (32-81) 42 (23-81) 25 (11-49) 
NEFA, baseline 
(mEq/L)  
Pre 0.70 (0.45-0.78) 0.66 (0.47-0.88) 0.65 (0.47-0.75) 
Post 0.52 (0.42-0.87) 0.58 (0.54-0.74) 0.61 (0.56-0.70) 
Adiponectin (μg/mL) Pre 1.7 ± 0.4 1.9 ± 0.4 1.7 ± 0.4 
Post 2.3 ± 0.6 4.4 ± 0.9* 7.3 ± 1.3* 
Leptin (ng/mL) Pre 19 ± 3 16 ± 2 16 ± 2 
Post 17 ± 2 15 ± 2 17 ± 2 
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Table 4.3 AUC0-180 for glucose, insulin, NEFAs, and % NEFA suppression, and coefficient of 
glucose disappearance, during an IV glucose tolerance test in 12 obese cats before and after 6 
weeks of treatment with placebo, 1 mg/kg pioglitazone, or 3 mg/kg pioglitazone. Values with 
non-normal distribution are expressed as median (IQR); normally distributed values are 
expressed as mean ± SE. *= significant change from pre-treatment value vs. change with placebo 
(P<0.05).  
 
 
  Placebo 1 mg/kg pioglitazone 3 mg/kg pioglitazone 
Glucose AUC 0-180, 
(min*mol/L) 
Pre 2.2 (1.9-2.5) 2.1 (2.0-2.2) 2.2 (1.8-2.5) 
Post 2.1 (1.8-2.3) 1.8 (1.7-2.0) 1.8 (1.6-2.1) 
Insulin AUC 0-180, 
(min*nmol/L) 
 
Pre 27 (20-39) 25 (18-34) 26 (19-42) 
Post 35 (24-47) 25 (20-34) 16 (13-34)* 
NEFA AUC 0-180, 
(min*mEq/L)  
Pre 48 (42-59) 54 (48-64) 54 (46-58) 
Post 51 (48-66) 50 (45-66)* 68 (49-82) 
NEFA AUC 0-90, 
(min*mEq/L) 
Pre 26 (23-28) 30 (21-32) 27 (24-43) 
Post 27 (21-37) 26 (20-28)* 24 (20-33) 
% NEFA suppression 
AUC 0-180, 
(1000*min*%) 
Pre 10.1 (8.8-11.2) 9.5 (7.8-10.6) 8.5 (8.1-10.1) 
Post 8.2 (6.8-8.8) 9.8 (9.2-10.7)* 8.1 (6.8-9.8) 
% NEFA suppression 
AUC 0-90, (1000*min*%) 
Pre 5.1 (4.4-5.7) 4.5 (3.8-5.7) 4.2 (3.6-5.0) 
Post 4.0 (3.3-4.7) 5.5 (4.0-5.8)* 5.4 (4.2-5.5)* 
Coefficient of glucose 
disappearance 
(1000*min
-1
)  
Pre 12 ± 2 12 ± 1 12 ± 1 
Post 11 ± 2 13 ± 1 13 ± 2 
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Table 4.4  Body weight, RER, heat production, and heat production per metabolic body size 
(BW
0.75
) for 12 obese cats before and after 5 weeks of treatment with placebo, 1 mg/kg 
pioglitazone, or 3 mg/kg pioglitazone.  Values with non-normal distribution are expressed as 
median (IQR), with the exception of body weight, which is expressed as median (range); 
normally distributed values are expressed as mean ± SE.  Mean ± SE daily food intake is also 
shown for each treatment period.  *= significant change from pre-treatment value vs. change 
with placebo (P<0.05).  
 
  Placebo 1 mg/kg pioglitazone 3 mg/kg pioglitazone 
Body weight (kg) 
 
Pre 6.2  (5.0-9.7) 6.2 (5.2-9.7) 6.2 (5.4-9.9) 
Post 6.3  (5.0-9.9) 6.2 (5.0-9.7) 6.3 (5.3-9.9) 
Average daily food 
intake (g) 
 
 62 ± 3 62 ± 4 62 ± 4 
RER Pre 0.75 (0.74-0.77) 0.76 (0.75-0.76) 0.75 (0.74-0.77) 
Post 0.75 (0.74-0.77) 0.74 (0.74-0.76)* 0.75 (0.74-0.76)* 
Heat production (kcal/h) Pre 11.1 ± 0.4 11.4 ± 0.6 11.1 ± 0.4 
Post 10.9 ± 0.5 11.1 ± 0.5 10.9 ± 0.5 
Heat production per 
MBS (kcal/h) 
Pre 2.8 (2.5-3.1) 2.8 (2.5-3.1) 2.7 (2.5-3.0) 
Post 2.7 (2.5-3.0) 2.7 (2.6-3.0) 2.8 (2.4-3.0) 
 
 
 
Table 4.5  Mean ± SD Cmax, AUC0-inf, and t1/2λz  estimated from the concentration-time profiles 
of obese cats dosed with 1 mg/kg or 3 mg/kg oral pioglitazone (Actos
TM
 ) (both n=11). 
*=significant difference vs. 1 mg/kg dosage (P<0.05). 
 
 1 mg/kg pioglitazone 3 mg/kg pioglitazone 
Cmax (ng/mL) 997 ± 208 1528 ± 527* 
AUC0-inf (h*μg/mL) 7.44 ± 2.25 11.9 ± 5.4* 
t1/2 λz (h) 3.65 ± 0.65 3.67 ± 0.56 
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Chapter V 
 
  
Investigation of 
1
H MRS for quantification of hepatic triglyceride in lean and obese cats
2
 
 
5.1 Abstract 
   
1
H magnetic resonance spectroscopy (
1
H MRS) is the preferred technique for noninvasive 
quantification of hepatic triglyceride in humans.  Domestic cats are subject to liver lipid 
accumulation, but MRS has not been investigated for quantification of liver fat in cats.  The 
purpose of this project was to investigate a technique for 
1
H MRS measurement of hepatic 
triglyceride in lean and obese cats.  Hepatic 
1
H MRS was performed, using a 3T imaging unit 
and a single-voxel spin-echo spectroscopy sequence with respiratory synchronization, on 6 lean 
(3.3-4.6 kg) and 12 obese cats (5.2-9.8 kg). In addition, liver samples from 4 lean (2.3-4.6 kg) 
and 5 obese cats (5.3-7.6 kg) were used for chemical determination of triglyceride content. 
Median liver fat percentages in lean and obese cats were 1.3% and 6.8%, respectively, by 
1
H 
MRS.  In cats with samples analyzed by chemical assay, median liver fat percentages were 1.7% 
(lean) and 6% (obese). Chemical assay results support the biological plausibility of 
measurements obtained using 
1
H MRS.  Full validation of the 
1
H MRS method may be necessary 
before other conclusions can be drawn; however, this report should provide a foundation for the 
further development of spectroscopic techniques for studying hepatic lipid accumulation in cats.   
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5.2 Introduction 
Magnetic resonance spectroscopy (MRS) is a sensitive, noninvasive technique that can be used 
to investigate the molecular composition of living tissues.  Like magnetic resonance imaging 
(MRI), MRS is performed by detecting electrical signals produced by isotopic nuclei in a large 
external magnetic field, after they are excited by a radio frequency pulse (Castillo et al., 1996).  
MRS exploits the fact that in the presence of the magnetic field, atoms exhibit shifts in their 
Larmor, or resonant, frequencies that depend on their location within a molecule.  The electrical 
signals they generate are probed over a range of frequencies, producing a spectrum that that 
gives quantitative information about the chemical content of the sample.  Various isotopes can be 
used for MRS; among them, the hydrogen nucleus (
1
H) is abundant in biological systems and is 
particularly sensitive to radiofrequency excitation (Castillo et al., 1996).  
1
H MRS, or proton 
spectroscopy, can distinguish the protons of water molecules from those of fatty acids in a given 
volume of tissue. Thus, it provides an accurate determination of tissue fat content (Longo et al., 
1995; Cassidy et al., 2009).  
Within the past 20 years, 
1
H MRS has become widely used in human clinical research for 
noninvasive measurement of hepatocellular triglyceride (Fabbrini et al., 2009; Schwenzer et al., 
2009).  Lipid accumulation in hepatocytes is a feature of human obesity and type 2 diabetes 
(Wanless and Lentz,1990; Kelley et al., 2003).  It is also the defining characteristic of human 
non-alcoholic fatty liver disease (NAFLD), a chronic hepatopathy with variable progression from 
simple steatosis to severe steatohepatitis and fibrosis (Lebovics and Rubin, 2011).  For 
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identification of steatosis, magnetic resonance techniques, including 
1
H MRS, are more sensitive 
and specific than ultrasound (US) or computed tomography (CT) (Lee et al., 2008).  As well, 
1
H 
MRS-derived measurements of liver fat correspond closely with those obtained by chemical 
triglyceride assay of liver biopsies (Thomsen et al., 1994; Szczepaniak et al., 1999). 
Consequently, 
1
H MRS has been used in lieu of biopsy in large patient cohorts to explore 
associations between high hepatic lipid content and other physiologic derangements such as 
insulin resistance (Holt et al., 2006; Korenblat et al., 2008).  It has also proven particularly useful 
in longitudinal studies of patients with hepatic steatosis, as it permits serial measurements and 
evaluation of the results of therapeutic interventions without the risks of biopsy (Bajaj et al., 
2003).   
Liver triglyceride accumulation occurs in domestic cats as a result of diabetes (Johnson et 
al., 1986) or prolonged fasting (feline hepatic lipidosis) (Armstrong et al., 2009).  Obese cats 
may also have elevated liver fat, although previous studies on this subject have yielded 
conflicting results (Dimski et al., 1992; Biourge et al. 1994a; Nicoll et al. 1998b; Blanchard et 
al., 2001).  The ability to noninvasively quantify liver fat in cats would facilitate study of 
pathophysiologic mechanisms and novel therapeutics for excess hepatic lipid storage in this 
species.  Although ultrasound or computed tomography may be used as screening tools for 
severe hepatic lipid accumulation (Nicoll et al., 1998a; Nakamura et al., 2005), neither method is 
ideal for repeated quantitative assessment.  
1
H MRS has been used to demonstrate elevated 
triglyceride in the muscle of obese cats (Wilkins et al., 2004).  However, it has not previously 
been investigated for quantification of feline liver fat.  The purpose of this project was to explore 
a technique for 
1
H MRS measurement of hepatic triglyceride in cats. 
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5.3 Materials and Methods 
Animals  
 Eighteen adult purpose-bred Domestic Shorthair cats were used for 
1
H MRS.  Cats were 
classified as lean (n=6) or obese (n=12) based on percent gain of adult lean body weight.  Obese 
cats had gained >50% of their adult lean body weight (median 98%; range 54%-109%), and had 
been obese for > 1 year.  Median weight of the obese cats was 6.2 kg (range 5.2-9.8 kg); median 
weight of the lean cats was 3.5 kg (range 3.3-4.6 kg).  Of the obese cats, 6 were neutered males 
and 6 were spayed females, and median age was 5 years (range 5-7 years).  Of the lean cats, 4 
were neutered males and 2 were spayed females, and all were 4-5 years of age. Cats were housed 
in the University of Illinois animal care facility and were fed a commercial dry feline 
maintenance diet (Pro Plan Chicken & Rice Formula, Nestlé Purina) once daily.  All procedures 
involving the cats were carried out in accordance with the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals and were approved by the University of 
Illinois Institutional Animal Care and Use Committee.    
 
Tissues 
  Liver samples from 4 lean and 5 obese healthy cats, euthanized for reasons unrelated to 
the current project, were used for chemical triglyceride assay.  Samples had been snap-frozen in 
liquid nitrogen immediately after collection and stored at -80 C.  Obese cats from which the 
samples were obtained (1 neutered male, 4 spayed females; 5 to 12 years of age) had a median 
weight of 6.7 kg (range, 5.3-7.6 kg). Lean cats (3 neutered males, 1 spayed female; 4 to 8 years 
of age) had a median weight of 3.9 kg (range, 2.3-4.6 kg).    
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1
H MRS 
      For spectroscopic examination, cats were sedated with tiletamine-zolazepam (Telazol, 
Pfizer Animal Health).  Scanning was performed in a 3T scanner (Magnetom Trio, Siemens 
Medical Systems).  The cats were placed in a supine position in a custom-made holder with a 
semi-circular cross section.  An infant respiratory belt (Lafayette Instrument Company) was 
positioned over the abdomen of the cats to monitor breathing.  Imaging was performed with a 
flexible body matrix coil and a spine matrix coil which were positioned above and below the 
cats, respectively.  Ear plugs were placed in the ears as protection from scanner noise.     
The cats were first scanned using T1-weighted scans obtained with a 2D flash gradient 
echo sequence, with 9-12 slices in the sagittal, dorsal, and transverse orientations.  Slice 
thickness was 7 mm, and slices covered a field of view of 200 mm x 200 mm with a resolution of 
256 points (TR =  6.8 ms, TE = 4 ms, flip angle = 20⁰).  For most cats, additional T2-weighted 
scans were performed using a 2D turbo spin echo sequence, with respiratory gating based on 
signal from the respiratory belt, and 2 averages.  Scans were performed in three orientations:  
dorsal (17 slices, slice thickness: 3 mm, 180 mm x 108 mm, 256 x 154 voxels, flip angle = 120⁰ , 
TR = 3600 ms, TE = 103 ms), sagittal (15 slices, slice thickness: 3 mm, 180 mm x 107 mm, 192 
x 114 voxels, flip angle = 120⁰- 140⁰, TR = 3600 ms, TE = 107 ms), and transverse (16 slices, 
slice thickness: 3 mm, 220 mm x 165 mm, 192 x 144 voxels, flip angle = 120⁰, TR = 3600 ms, 
TE = 103 ms).  
Scanning parameters were adjusted for some cats so that the Specific Adsorption Rate 
(SAR) estimation provided by the scanner remained within First Level Controlled Operating 
Mode.   For some cases, to meet this requirement, the number of slices was reduced and the slice 
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thickness was increased to 8 mm, or the resolution was decreased, to avoid significant heating 
due to radiofrequency deposition.  
The relative concentrations of fat and water were assessed by performing single voxel  
magnetic resonance spectroscopy imaging (MRSI) measurements,  TR = 3000 ms, TE = 50 ms, 
20 averages, 8x8x8 mm, flip angle 90⁰, 1024 points, bandwidth 2000 Hz, with respiratory gating 
based on signal from the respiratory belt.  A combination of the T1 and the T2-weighted scans 
was used to select locations for spectroscopy.  Spectroscopy was performed at two different 
locations within the liver, and voxels were positioned as far as possible from the gallbladder, 
surrounding fat, lung, and vascular structures.  The latter approach minimized distortions due to 
chemical shift artifact.  This artifact stems from the fact that the excitation pulse causes the 
volume of excited fat to be displaced relative to the volume of the excited water.  By default, the 
selected volume provided by the scanner control software corresponds to the location of the 
excited water pulse.  However, this setting can be modified by changing the frequency of the 
excitation with the Delta Frequency parameter provided in the sequence protocol.  When this 
parameter is set to the difference between the fat and water resonances, approximately -3.4 to -
3.7 ppm, the selected region will show the location of the excited fat.  For an ideal measurement, 
the voxel would be placed in a region of homogeneous liver that is sufficiently far from fat, lung, 
and vascular structures that the measurement would be independent of the Delta Frequency 
parameter.  This assumption was tested at each of the two locations by performing three 
measurements per location, in which the Delta Frequency parameter was set at 0, -1.9 ppm, and -
3.8 ppm.   
The relative proton densities of fat and water, F  and W , were calculated from the 
spectra using commercially available software (LCModel; Provencher, 2001).  The proton 
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density of fat was taken from the main fat peak at 1 ppm that includes sub-peaks expected at 0.9, 
1.3, and 1.6 ppm.  Other available fat peaks were typically much smaller and were neglected in 
our analysis.  The fat fraction, FTSA, of the proton density was calculated from  
FTSA=ρF / (ρF 
+ ρW), where ρF and ρW are the proton densities of fat and water, respectively.  
When the range of the FTSA values calculated from a single location was greater than 0.03, 
measurements from that voxel were not considered to be independent of changes in the Delta 
Frequency parameter, and all measurements from the voxel were excluded from analysis.  Mean 
values of FTSA for each cat were obtained by averaging all non-excluded measurements.  
The average values of FTSA calculated from the spectroscopy measurements were 
converted to a volume or weight fraction of triglyceride in the liver (φf; expressed as percent) 
according to the following equation:   
FTSA
FTSA
φ
508.0138.1
100
f . 
This equation is derived from those validated for 
1
H MRS in humans by Longo et al. (1995).  
The original series of equations incorporated the ratio of spectroscopically detectable lipid 
protons in the 0.5-3.0 ppm range to total lipid protons (0.85), proton densities of water and fat 
(110 and 111 mol/L, respectively), density of liver tissue (approximately 1 g/L), density of fat in 
the liver (0.9 g/L), and percent water weight of human liver (0.71 g water/g normal tissue).  
Because average percent water weight of the liver in cats has been reported as 0.66 g water/g 
normal tissue (Fenn and Haege, 1940), the latter value was used for calculations in the current 
investigation.  Other factors listed were assumed to be relatively constant among humans and 
domestic animals.   
Total scan time per cat was 20-30 min.  Girth (abdominal circumference) was measured 
immediately caudal to the last rib in sedated cats on the day of scanning.  In 4 obese cats, scans 
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were repeated after 6 weeks of administration of a lactose placebo, as part of a separate study; 
these data were used to characterize the repeatability of the measurements.     
 
Chemical triglyceride assay 
Lipids were extracted from liver samples using a modification of the method of Folch 
(Folch et al., 1957; Kishida et al., 2002).  Briefly, 300-900 mg liver samples were homogenized 
in chloroform:methanol (2:1, v/v) with a rotor-stator homogenizer (Polytron PCU-2-110; 
Brinkmann Instruments, Inc.).  Homogenates were centrifuged at 20 ⁰C at ~ 500 x g for 5-10 
min, and the supernatant was decanted, filtered through filter paper (Whatman Filter Paper No. 1, 
GE Healthcare), and brought to a volume of 25 mL with 2:1 chloroform:methanol.  Duplicate 
aliquots of the extract were evaporated to dryness under nitrogen, and resuspended in 
isopropanol/Triton-X (90:10).  Triglyceride concentration was determined using a colorimetric 
method (Triglyceride Reagent Kit, Pointe Scientific). 
 
Statistical analysis   
For both 
1
H MRS and chemical assay data, median liver fat percentage was compared 
between lean and obese cats using a Mann-Whitney U-test. Mann-Whitney U-tests were one-
sided, with Ha=ηlean<ηobese, where ηlean and ηobese  represent median percent liver triglyceride in 
lean and obese cats, respectively.  P-values <0.05 were considered significant. 
 
5.4 Results 
1
H magnetic resonance spectra were successfully obtained in all 18 cats.  A representative 
spectrum, with its corresponding localizing scans and voxel placement, is shown in Figure 5.1.  
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In three obese cats and one lean cat, fat fraction values from one voxel varied with changes in the 
Delta Frequency parameter, such that the difference between the highest and lowest 
measurements was >0.03.  This was considered evidence of artifact arising either from motion or 
from placement of the voxel near areas where fat was not homogeneous.  Data from these voxels 
were excluded from analysis, and average liver fat percentage in these cats was calculated from 
the three measurements in the remaining voxel.  
 In the other 14 cats, placement of both voxels was adequate to avoid artifact from motion 
or chemical shift, and all measurements were used for calculation of mean fat fraction.  
Maximum difference in liver fat content between the two locations in these cats was 1.2% (lean 
cats) or 3% (obese cats).   Median liver fat percentages in lean and obese cats by spectroscopy 
were 1.3% (range, 0.6 to 5.7%) and 6.8% (range, 3.9 to 16.4%), respectively.  For samples 
analyzed by chemical assay, median liver fat percentage was 1.7% (range, 0.7 to 2.3%) in lean 
cats and 6% (range, 2.7 to 7.3%) in obese cats.  For both 
1
H MRS and chemical assay 
measurements, values for liver triglyceride were significantly greater in obese than in lean cats 
(p≤0.03).   1H MRS-determined liver fat percentages in relation to body weight and girth are 
shown in Figures 5.2A and 5.2B, respectively.  Values for liver triglyceride vs. body weight in 
the separate group of cats with samples analyzed by chemical assay are shown in Figure 5.3.   
In the 4 obese cats in which scans were repeated after 6 weeks, mean coefficient of 
variation for the two determinations of average liver fat percentage was 7.4%, and maximum 
coefficient of variation was 12.3%.  A mean coefficient of variation of 8.4% has been reported in 
humans for two temporally separated determinations on the same day (Szczepaniak et al., 2005).   
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5.5 Discussion 
A previous publication involving chemical liver triglyceride measurement in wedge 
biopsies from cats fed a maintenance diet reported a mean liver triglyceride content of 1% for 5 
cats of ideal body weight (Hall et al., 1997).  A separate publication, using similar methods, 
reported liver fat percentages of 1.5%-6% for 4 groups of 3 obese cats (≥ 40% overweight 
compared to lean cats of the same length and body type) (Biourge et al., 1994b).  Other 
quantitative analyses of feline liver fat (Blanchard et al., 2002; Nicoll et al., 1998a) have 
produced varying results, perhaps because of differences in techniques used to measure 
triglyceride, methods of biopsy procurement, definitions of obesity, and diets fed to obese cats 
prior to assessment. To gain further information regarding the expected range for liver 
triglyceride in obese compared to lean cats, the present investigation utilized chemical assay to 
measure liver triglyceride percentage in a small group of both lean and obese cats fed a 
maintenance diet.  Chemical triglyceride assay is considered the most accurate method of 
determining lipid content in liver biopsies, as it is capable of measuring the lipid in vacuoles that 
are too small to be recognized on histological evaluation (Longo et al., 1995; Szczepaniak et al., 
2005).  The results of chemical assay in liver samples from this study support the premise that 
hepatic triglyceride accumulation occurs in feline obesity, and that liver fat content in obese cats 
is frequently >5%.  In humans, >5% liver fat is considered abnormal, and is adequate for a 
classification of hepatic steatosis (Szczepaniak et al., 2005). 
In dogs, rabbits, and humans, 
1
H MRS has been validated against chemical triglyceride 
assay by comparing the results of the two assessments in the same individual (Longo et al., 1995; 
Szczepaniak et al., 1999).  The latter procedure was not replicated in the cats of this study, as it 
was not possible to obtain liver biopsies from the same cats that were scanned.   Nonetheless, the 
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1
H MRS method described here appears repeatable, based on consistency of measurements in the 
same cats several weeks apart.  As well, measurements obtained by 
1
H MRS differentiated well, 
in general, between cats classified as lean and those classified as obese. An interesting finding 
was a 
1
H MRS measurement of 5.7% liver fat in one of the six lean cats.  This lean cat also had a 
surprisingly high body fat percentage (27%) on DEXA scanning, despite a body weight and girth 
that were comparable to those of the other lean cats.  In humans, although there is a general 
positive relationship between obesity and high liver fat, 3-15% of humans with normal body 
weight have elevated liver triglyceride (Fabbrini et al., 2010).  Genetic background, habitual 
activity level, and diet are all known to alter the relationship between liver fat percentage and 
adiposity (Browning et al., 2004; Westerbacka et al., 2005; Perseghin et al., 2007; Romeo et al., 
2008).  A “metabolically obese normal-weight” phenotype has been described in people who 
have normal BMI but high body fat and ectopic lipid deposition (Karelis et al., 2004); it is 
conceivable that a similar condition occurs in cats.    
In summary, measurements produced by the 
1
H MRS technique described here are 
biologically plausible, based on the results of chemical assay in a separate group of lean and 
obese cats.  Full validation of the method may be necessary before other conclusions can be 
drawn.  However, this report contributes to existing knowledge regarding expected liver fat 
content in feline obesity, and should provide a foundation for further development of quantitative 
spectroscopic techniques to study hepatic lipid accumulation in cats.   
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5.6 Figures and Legends 
Figure 5.1 Representative spectrum (D), with corresponding localizing scans and voxel 
placement (A: sagittal view; B: dorsal view; C: transverse view) from hepatic 
1
H MRS in an 
obese cat (body weight 6.5 kg; 
1
H MRS-measured liver triglyceride 6.5%).  Peaks at 1.0-2.0 ppm 
and 4.0-5.0 ppm correspond to lipid and water protons, respectively.  Objects in the transverse 
view are phantoms used for a separate experiment.  
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Figure 5.2 
1
H MRS-determined liver fat percentage relative to body weight (A) and girth (B) in 
6 lean and 12 obese cats. 
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Figure 5.3  Chemically determined liver fat percentage relative to body weight in 4 lean and 5 
obese cats. 
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Chapter VI 
 
 
 
 
Conclusion 
 
 
 
 
6.1 Conclusion 
 
 The goals of the work described in this dissertation were 1) to determine the metabolic 
effects of pioglitazone in cats, in order to assess its potential for treatment of feline DM, and 2) 
to investigate a technique for noninvasive measurement of feline liver fat.  As reviewed in 
Chapter 2, DM is a relatively common endocrinopathy in cats, with treatment options limited to 
insulin and one oral insulin secretogogue.  Considering the similarities between type 2 DM in 
humans and DM in cats, it seemed reasonable to continue exploration of the TZDs, which 
improve both insulin sensitivity and ß-cell function in human type 2 DM, in cats.  Feline hepatic 
lipidosis has a poorly understood pathogenesis and no pharmacological treatment.  The 
noninvasive technology of 
1
H MRS, which is used in human clinical research for determination 
of liver fat content, offered a possible alternative to biopsy for eventual study of the effects of 
therapeutic interventions on this disease.   
Chapter 3 of this dissertation describes a single-dose pharmacokinetic study of 
pioglitazone that was carried out in lean and obese cats.  Results indicated that pioglitazone was 
rapidly absorbed, with an average bioavailability of 55%, and that plasma pioglitazone 
concentrations considered therapeutic in humans were achievable in cats with oral 
administration.  There were no differences in pharmacokinetic parameters for pioglitazone 
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between lean and obese cats.  The data obtained from this study provided a basis for dosage 
selection in further investigations.   
 In the work discussed in Chapter 4, 1 and 3 mg/kg dosages of pioglitazone were 
administered orally to 12 obese, insulin-resistant cats, in a placebo-controlled, 3-way crossover 
design. Six weeks of 3 mg/kg pioglitazone lowered insulin concentrations in the obese cats 
during glucose tolerance testing, and significantly increased insulin sensitivity with respect to 
both glucose clearance and NEFA disposal.  Pioglitazone also appeared to have a favorable 
effect on lipid metabolism in obese cats, as it increased NEFA suppression during the initial 
portion of IVGTT, and lowered cholesterol and triglyceride concentrations.  Based on clinical 
and laboratory evaluation, no overt toxicity of the drug was evident in otherwise healthy obese 
cats.  This is in contrast to results for metformin, a hepatic insulin sensitizer which is relatively 
safe in humans but produced unacceptable adverse effects in both healthy and diabetic cats 
(Nelson et al., 2004).       
In the study described in Chapter 5, liver fat in 12 obese and 6 lean cats was measured by 
1
H MRS, and  average liver fat percentages of 6.8% and 1.3% were obtained for obese and lean 
cats.  These results were supported by chemical determination of liver fat percentage in a 
separate group of cats.  The 
1
H MRS technique employed differentiated well between lean and 
obese cats in terms of liver fat, and appeared repeatable in 4 cats scanned 6 weeks apart.  In 
addition to supplementing existing knowledge regarding liver fat content in feline obesity, this 
study provided a foundation for further development of quantitative spectroscopic techniques to 
study hepatic lipid accumulation in cats.   
 
Overall, the results of these investigations demonstrate a positive effect of 3 mg/kg 
pioglitazone on insulin sensitivity and lipid metabolism in obese cats.  Further study of the drug 
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might entail clinical trials in cats with DM or other lipid metabolic disorders.  In diabetic cats, an 
interesting possibility is that pioglitazone might improve ß-cell function, as it does in human 
diabetes, perhaps leading to improved long-term glycemic control and/or an increased chance of 
diabetic remission.  Studies in diabetic cats could incorporate the recently developed feline 
proinsulin assay (Kley et al., 2008), in conjunction with insulin concentrations and clinical 
status, to evaluate ß-cell functional improvement.  The proinsulin:insulin ratio has been used as 
an index of ß-cell dysfunction in human diabetics, and decreases with pioglitazone or other TZD 
treatment (Ovalle & Bell, 2004; Wallace et al., 2004).        
With respect to the technique for 
1
H MRS in cats, although it could not be used to assess 
the effects of pioglitazone in the work described here, it may be helpful in future investigations, 
either of dietary components or of pharmacologic agents for reducing liver lipid accumulation.  
Limitations of 
1
H MRS include cost, the need for deep sedation or anesthesia of subjects, and the 
requirement for spectroscopic software and expertise.  However, when appropriate software and 
an individual with knowledge of spectroscopy are available, 
1
H MRS can be carried out on any 
commercially available scanner with a field strength of 1.5 T or higher (Schwenzer et al., 2009).  
If the method can be appropriately validated, it may ultimately prove useful for exploring the 
pathophysiology associated with feline hepatic lipid accumulation, as well as for examining 
novel therapies for feline hepatic lipidosis.    
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LIST OF ABBREVIATIONS AND SYMBOLS 
 
λz terminal elimination rate constant 
 1H MRS proton magnetic resonance spectroscopy 
2D 2-dimensional 
   A y-intercept for the distribution phase  
 ACS acyl coA synthase 
   AF2 activation function 2 
  AIC Akaike's information criterion 
  ALP alkaline phosphatase 
  AMP adenosine monophosphate 
  aP2/FABP4 adipocyte Protein 2/fatty acid binding protein 
ATP adenosine triphosphate 
  AUC area under the curve 
  AUC0-inf area under the curve from time 0 to infinity 
AUMC 0-inf area under the moment curve from time 0 to infinity 
B y-intercept for the elimination phase  
 BW body weight 
   C/EBPα CCAAT enhancer binding protein alpha 
 cAMP cyclic adenosine monophosphate 
 CD36 cluster of differentiation 6 
  Cdk5 cyclin-dependent kinase 5 
  CETP cholesteryl ester transfer protein 
 Cl/F oral clearance 
   Cls systemic clearance 
   Cmax maximum plasma concentration 
 CYP2C8 cytochrome P450 2C8 
  CYP3A4 cytochrome P450 3A4 
  DAG diacylglycerol 
   DEXA dual-energy X-ray absorptiometry 
 DKA diabetic ketoacidosis 
  DM diabetes mellitus 
   DMSO dimethyl sulfoxide 
   DNA deoxyribonucleic acid 
  EDTA ethylenediaminetetraacetic acid 
 EHC euglycemic-hyperinsulinemic clamp 
 ELISA enzyme-linked immunosorbent assay 
 ER endoplasmic reticulum 
  F bioavailability 
   FATP1 fatty acid transport protein 1 
  FOXO1 forkhead box protein O1 
  FS fractional shortening 
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FTSA fat-to-total-signal peak area 
  GLUT2 glucose transporter 2 
  GLUT4 glucose transporter 4 
  HCl hydrochloride 
   HDL high-density lipoprotein 
  HL hepatic lipidosis 
   HMBS heat per metabolic body size 
  HPLC high performance liquid chromatography 
IGT impaired glucose tolerance 
  IL-6 interleukin-6 
   IQR interquartile range 
   IR insulin receptor 
   IRS insulin receptor substrate 
  IS internal standard 
   IV intravenous 
   IVGTT intravenous glucose tolerance test 
 IVSd interventricular septal thickness (diastole) 
IVSs interventricular septal thickness (systole) 
JNK c-Jun N-terminal kinase 
  K+ potassium 
   LA/Ao left atrial/aortic ratio 
  LC-FA CoA long chain fatty acyl coenzyme A 
 LDL low-density lipoprotein 
  LOD limit of detection 
   LPL lipoprotein lipase 
   LVIDd left ventricular internal diameter (diastole) 
LVIDs left ventricular internal diameter (systole) 
LVPWd left ventricular posterior wall (diastole) 
MafA musculoaponeurotic fibrosarcoma oncogene homolog A 
MAP kinase mitogen-activated protein kinase 
 MM minimal model 
   MRSI magnetic resonance spectroscopy imaging 
MRT mean residence time 
  NAFLD non-alcoholic fatty liver disease 
 NEFA non-esterified fatty acid 
  NGT normal glucose tolerance 
  NId insulin-dependent NEFA concentration at basal 
NIi non-insulin-dependent NEFA concentration at basal 
NLME nonlinear mixed-effects 
  P2 rate constant of time lag between supra-basal changes in insulin  
concentrations and insulin action, X(t) 
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P2N time-lag between supra basal changes in plasma insulin and NEFA  
suppression 
PDX-1 pancreatic and duodenal homeobox 1 
 PEPCK phosphoenolpyruvate carboxykinase 
 PI(3)K phosphatidylinositol (3) kinase 
 PKC protein kinase C 
   PPARγ peroxisome proliferator activated receptor gamma 
PPRE PPAR response element 
  PRESS point-resolved echo spin sequence 
 PZI protamine zinc insulin 
  Ra rate of appearance 
   RER respiratory exchange ratio 
  RXR retinoid X receptor 
   SAR Specific Adsorption Rate 
  SD standard deviation 
   SEM standard error of the mean 
  SG fractional glucose clearance at basal insulin 
SI insulin sensitivity of fractional glucose disappearance 
SIN sensitivity of fractional NEFA inhibition to changes in plasma  
insulin around basal 
T tesla 
    t1/2 α distribution half-life 
  t1/2 ß terminal elimination half-life 
  t1/2 k10 elimination half-life 
  t1/2 λz terminal elimination half-life 
  T1 spin-lattice relaxation time constant 
 T2 spin-spin relaxation time constant 
 Tmax time to maximum plasma concentration 
 TE echo time 
   TR repetition time 
   TNF-α tumor necrosis factor alpha 
  TZD thiazolidinedione 
   UCP1 uncoupling protein 1 
  Vß volume of distribution of the terminal elimination phase 
Vc volume of distribution of the central compartment  
Vd/F apparent oral volume of distribution 
 VG apparent glucose distribution volume 
  VLDL very low-density lipoprotein 
  Vss volume of distribution at steady state 
 Vz/F apparent oral volume of distribution 
 
 
